Major Pharmaceuticals Industry Financials, Performance and Ratios
-
Industry Score
43.3 /100
Rank 53 out of 131 Industries -
Advance/Decline
279/107
-
No. of Companies386
-
Avg. Market Cap9,005
-
Price to Earning Ratio3.78
-
Price to Earning Growth Ratio1.23
-
Price to Book Ratio39.78
-
Return on Equity54.72
-
Return on Capital Employed-
-
Return on Assets12.60
-
Dividend yield 1 year %0.91 %
-
Net Profit Growth Annual YoY %-27.84 %
-
Net Profit Growth Qtr YoY %-47.13 %
-
Net Profit Growth Qtr QoQ %-48.08 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Major Pharmaceuticals Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Major Pharmaceuticals Peer comparison
Compare all stocks in Major Pharmaceuticals industry listed on stock exchanges
Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie Inc |
|
306,015.6
|
173.0
|
L
 0.8%
H
171.9
175.2
|
L
 -1.2%
H
169.8
180.5
|
L
 -19.1%
H
164.4
214.5
|
L
 0.8%
H
164.4
218.7
|
L
 5.1%
H
153.6
218.7
|
L
 8.6%
H
131.0
218.7
|
L
 107.3%
H
79.1
218.7
|
L
 177.7%
H
45.5
218.7
|
Adc Therapeutics SA |
|
119.9
|
1.2
|
L
 4.3%
H
1.1
1.2
|
L
 -0.8%
H
1.1
1.3
|
L
 -31.6%
H
1.1
1.8
|
L
 -33.9%
H
1.1
1.9
|
L
 -74.6%
H
1.1
5.2
|
L
 -91.0%
H
0.4
13.7
|
L
H
0.4
56.6
|
L
H
0.4
56.6
|
Amneal Pharmaceuticals Inc... |
|
2,306.5
|
7.4
|
L
 2.5%
H
7.0
7.4
|
L
 5.4%
H
7.0
7.4
|
L
 -14.6%
H
6.7
9.0
|
L
 -10.9%
H
6.7
9.2
|
L
 37.3%
H
5.2
9.5
|
L
 78.6%
H
1.2
9.5
|
L
 117.1%
H
1.2
9.5
|
L
 -85.3%
H
1.2
51.4
|
Annovis Bio Inc |
|
23.8
|
1.2
|
L
 -3.2%
H
1.2
1.3
|
L
 -6.2%
H
1.2
1.4
|
L
 -31.5%
H
1.1
2.1
|
L
 -75.7%
H
1.1
5.5
|
L
 -87.6%
H
1.1
20
|
L
 -90.3%
H
1.1
23.9
|
L
 -67.9%
H
1.1
132
|
L
H
1.1
132
|
Bausch Health Companies Inc |
|
1,884.5
|
5.1
|
L
 13.3%
H
4.5
5.3
|
L
 18.1%
H
4.3
5.3
|
L
 -27.3%
H
4.3
7.5
|
L
 -31.5%
H
4.3
8.0
|
L
 -40.7%
H
4.0
9.9
|
L
 -75.7%
H
4.0
23.2
|
L
 -70.7%
H
4.0
34.8
|
L
 -97.5%
H
4.0
263.8
|
Bristol-Myers Squibb Co. |
|
100,171.4
|
49.2
|
L
 -0.3%
H
49.1
50.1
|
L
 -2.9%
H
48.8
51.6
|
L
 -17.8%
H
48.8
61.6
|
L
 -12.5%
H
48.8
63.3
|
L
 1.9%
H
39.4
63.3
|
L
 -35.9%
H
39.4
81.4
|
L
 -18.8%
H
39.4
81.4
|
L
 -24.7%
H
39.4
81.4
|
Emergent Biosolutions Inc |
|
251.0
|
4.6
|
L
H
4.5
4.7
|
L
 5.2%
H
4.3
4.7
|
L
 -18.8%
H
4.0
5.9
|
L
 -53.2%
H
4.0
12.0
|
L
 148.4%
H
1.8
15.1
|
L
 -88.6%
H
1.4
41.9
|
L
 -93.1%
H
1.4
137.6
|
L
 -83.4%
H
1.4
137.6
|
GSK Plc - ADR |
|
72,793.3
|
35.9
|
L
 1.6%
H
35.1
36.1
|
L
 3.7%
H
34.7
36.2
|
L
 -11.0%
H
32.4
39.8
|
L
 7.5%
H
32.4
40.8
|
L
 -8.5%
H
31.7
45.9
|
L
 -23.6%
H
28.5
47.1
|
L
 -16.1%
H
28.5
47.8
|
L
 -25.4%
H
28.5
49.1
|
Johnson & Johnson |
|
379,478.7
|
157.5
|
L
 2.3%
H
154.2
159.4
|
L
 3.8%
H
151.2
159.4
|
L
 -4.1%
H
141.5
166.6
|
L
 7.1%
H
141.5
170.0
|
L
 8.1%
H
140.7
170.0
|
L
 -11.4%
H
140.7
186.7
|
L
 3.6%
H
133.7
186.7
|
L
 58.1%
H
81.8
186.7
|
Lilly(Eli) & Co |
|
754,275.0
|
840.0
|
L
 14.3%
H
821.8
858
|
L
 14.7%
H
730.3
858
|
L
 2.1%
H
677.1
874.9
|
L
 15.7%
H
677.1
935.6
|
L
 12.6%
H
677.1
972.5
|
L
 181.1%
H
276.8
972.5
|
L
 434.0%
H
129.2
972.5
|
L
 1059.0%
H
64.2
972.5
|
Merck & Co Inc |
|
196,278.7
|
78
|
L
 2.0%
H
76.9
78.8
|
L
 -1.5%
H
75.9
80.0
|
L
 -17.7%
H
75.9
95.4
|
L
 -20.3%
H
75.9
100.2
|
L
 -37.7%
H
75.9
134.6
|
L
 -9.4%
H
75.9
134.6
|
L
 -2.1%
H
68.4
134.6
|
L
 43.7%
H
43.6
134.6
|
Novo Nordisk - ADR |
|
257,820.2
|
58.1
|
L
 -7.6%
H
57.3
59.1
|
L
 -10.3%
H
57.3
66.8
|
L
 -28.3%
H
57.3
80.2
|
L
 -26.2%
H
57.3
93.8
|
L
 -52.7%
H
57.3
148.2
|
L
 -0.2%
H
47.5
148.2
|
L
 84.1%
H
30.8
148.2
|
L
 112.0%
H
15.5
148.2
|
Novartis AG - ADR |
|
218,958.4
|
110.9
|
L
 1.2%
H
109.5
111.3
|
L
 3.1%
H
107.1
111.3
|
L
 -1.2%
H
97.7
114.4
|
L
 13.7%
H
97.7
116.9
|
L
 19.8%
H
93.2
120.9
|
L
 20.2%
H
74.1
120.9
|
L
 24.2%
H
74.1
120.9
|
L
 22.4%
H
59.2
120.9
|
Organon & Co. |
|
2,868.4
|
11.1
|
L
 2.8%
H
10.9
11.2
|
L
 -0.5%
H
10.8
11.7
|
L
 -29.2%
H
10.8
15.9
|
L
 -29.4%
H
10.8
17.2
|
L
 -37.7%
H
10.8
23.1
|
L
 -66.7%
H
10.8
39.1
|
L
H
10.8
39.5
|
L
H
10.8
39.5
|
Prestige Consumer Healthca... |
|
3,976.9
|
80.3
|
L
 0.6%
H
79.7
80.9
|
L
 -2.2%
H
79.4
83.1
|
L
 -4.3%
H
77.7
88.5
|
L
 2.2%
H
74.4
90.0
|
L
 17.5%
H
62.4
90.0
|
L
 52.0%
H
48.5
90.0
|
L
 103.9%
H
32.2
90.0
|
L
 83.2%
H
26.3
90.0
|
Pfizer Inc. |
|
125,566.0
|
22.1
|
L
 0.5%
H
22.1
22.6
|
L
 1.1%
H
21.9
22.9
|
L
 -15.9%
H
20.9
26.5
|
L
 -15.8%
H
20.9
27.2
|
L
 -12.8%
H
20.9
31.5
|
L
 -57.3%
H
20.9
54.9
|
L
 -36.7%
H
20.9
61.7
|
L
 -33.3%
H
20.9
61.7
|
Perrigo Company plc |
|
3,455.1
|
25.3
|
L
 0.7%
H
25.0
25.5
|
L
 2.8%
H
24.6
25.6
|
L
 -9.2%
H
23.7
28.6
|
L
 6.2%
H
23.7
30.9
|
L
 -15.4%
H
23.1
33.5
|
L
 -28.5%
H
23.1
43.9
|
L
 -51.2%
H
23.1
58.8
|
L
 -87.3%
H
23.1
205.7
|
Dr. Reddy`s Laboratories L... |
|
11,389.2
|
13.7
|
L
 1.7%
H
13.5
13.7
|
L
 3.4%
H
13.1
13.7
|
L
 2.5%
H
12.3
13.9
|
L
 -8.3%
H
12.3
15.1
|
L
 -3.6%
H
12.3
74.9
|
L
 23.6%
H
9.9
74.9
|
L
 34.0%
H
9.6
74.9
|
L
 16.3%
H
5.6
74.9
|
Takeda Pharmaceutical Co -... |
|
46,296.8
|
14.7
|
L
 0.4%
H
14.6
14.8
|
L
 6.0%
H
14.1
14.8
|
L
 -3.1%
H
13.6
15.4
|
L
 13.9%
H
12.8
15.4
|
L
 11.8%
H
12.6
15.4
|
L
 0.1%
H
12.3
17.2
|
L
 -12.4%
H
12.3
20
|
L
 -42.5%
H
12.3
30.6
|
Teva- Pharmaceutical Indus... |
|
15,656.0
|
13.7
|
L
 1.6%
H
13.4
13.7
|
L
 1.4%
H
13.2
13.8
|
L
 -17.2%
H
12.5
16.6
|
L
 -37.7%
H
12.5
22.4
|
L
 6.8%
H
12.5
22.8
|
L
 35.0%
H
6.8
22.8
|
L
 32.9%
H
6.8
22.8
|
L
 -79.0%
H
6.1
72.3
|
Zoetis Inc - Ordinary Shar... |
|
66,315.9
|
148.7
|
L
 1.3%
H
146.8
150.0
|
L
 -0.5%
H
145.8
152.3
|
L
 -9.6%
H
139.7
166.3
|
L
 -10.4%
H
139.7
177.4
|
L
 -2.9%
H
139.7
200.2
|
L
 -18.7%
H
124.2
201.9
|
L
 13.7%
H
121.5
249.3
|
L
 217.9%
H
37.7
249.3
|
Biohaven Ltd |
|
2,079.1
|
20.4
|
L
 9.1%
H
18.5
20.5
|
L
 15.6%
H
17.5
20.5
|
L
 -29.4%
H
15.8
31.2
|
L
 -45.8%
H
15.8
44.3
|
L
 -51.7%
H
15.8
55.6
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
Abeona Therapeutics Inc |
|
236.2
|
4.8
|
L
 -0.2%
H
4.8
5.0
|
L
 5.2%
H
4.6
5.0
|
L
 -6.2%
H
3.9
5.4
|
L
 -7.3%
H
3.9
6.2
|
L
 -35.7%
H
3.1
7.7
|
L
 -27.8%
H
2.2
9.0
|
L
 -91.7%
H
2.2
94.8
|
L
 -94.2%
H
2.2
568.8
|
Oruka Therapeutics Inc. |
|
345.2
|
9.2
|
L
 7.1%
H
8.4
9.3
|
L
 20.1%
H
7.6
9.3
|
L
 -19.6%
H
5.5
12.7
|
L
 -24.7%
H
5.5
15.1
|
L
 -76.4%
H
2.2
53.9
|
L
 -66.9%
H
2.2
53.9
|
L
 -83.3%
H
2.2
264
|
L
 -99.3%
H
2.2
2343.6
|
Acumen Pharmaceuticals Inc |
|
54.5
|
0.9
|
L
 -8.2%
H
0.9
1
|
L
 -18.9%
H
0.9
1.2
|
L
 -28.6%
H
0.9
1.5
|
L
 -45.5%
H
0.9
1.8
|
L
 -71.5%
H
0.9
3.9
|
L
 -76.7%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
Arbutus Biopharma Corp |
|
603.2
|
3.2
|
L
 2.9%
H
3
3.2
|
L
 0.3%
H
3
3.3
|
L
 -1.6%
H
2.7
3.6
|
L
 -1.6%
H
2.7
3.7
|
L
 15.4%
H
2.6
4.7
|
L
 21.2%
H
1.7
4.7
|
L
 164.7%
H
1.0
9.0
|
L
 -83.4%
H
0.8
19.6
|
ABVC BioPharma Inc |
|
20.4
|
0.9
|
L
 -11.3%
H
0.9
1.0
|
L
 -5.5%
H
0.9
1
|
L
 30.3%
H
0.7
1.4
|
L
 59.3%
H
0.4
1.4
|
L
 -18.1%
H
0.4
1.7
|
L
 -96.6%
H
0.4
29
|
L
 -97.0%
H
0.4
299.5
|
L
 -99.9%
H
0.4
2865.3
|
Acadia Pharmaceuticals Inc |
|
2,456.8
|
14.7
|
L
 1.1%
H
14.4
14.7
|
L
 1.0%
H
14.3
15.2
|
L
 -14.8%
H
13.4
17.6
|
L
 -16.2%
H
13.4
20.7
|
L
 -13.7%
H
13.4
20.7
|
L
 -34.3%
H
12.2
33.9
|
L
 -69.9%
H
12.2
58.7
|
L
 -61.3%
H
12.2
58.7
|
Adicet Bio Inc |
|
43.8
|
0.5
|
L
 -7.0%
H
0.5
0.6
|
L
 -1.9%
H
0.5
0.6
|
L
 -33.8%
H
0.5
1.0
|
L
 -41.8%
H
0.5
1.1
|
L
 -73.8%
H
0.5
2.3
|
L
 -96.7%
H
0.5
21.9
|
L
 -93.6%
H
0.5
21.9
|
L
H
0.5
147.7
|
Achieve Life Sciences Inc. |
|
69.0
|
2.0
|
L
 -5.7%
H
2.0
2.1
|
L
 -8.7%
H
2.0
2.3
|
L
 -28.4%
H
1.8
3.1
|
L
 -35.6%
H
1.8
3.8
|
L
 -56.5%
H
1.8
5.6
|
L
 -74.3%
H
1.8
10.3
|
L
 -71.6%
H
1.8
18.3
|
L
 -100.0%
H
1.8
9020
|
AC Immune SA |
|
148.6
|
1.5
|
L
 -1.3%
H
1.5
1.5
|
L
 -5.1%
H
1.5
1.6
|
L
 -33.9%
H
1.4
2.3
|
L
 -44.8%
H
1.4
2.9
|
L
 -37.8%
H
1.4
5.0
|
L
 -60.7%
H
1.4
5.1
|
L
 -81.1%
H
1.4
13
|
L
H
1.4
20.0
|
Aclaris Therapeutics Inc |
|
123.3
|
1.1
|
L
 0.9%
H
1.1
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 -27.9%
H
1.1
1.8
|
L
 -55.6%
H
1.1
2.6
|
L
 -7.3%
H
1.0
5.2
|
L
 -92.9%
H
0.6
19.0
|
L
 -5%
H
0.6
30.4
|
L
H
0.6
33.9
|
Acrivon Therapeutics Inc |
|
56.7
|
1.8
|
L
 -2.2%
H
1.7
1.9
|
L
 11.7%
H
1.5
2.2
|
L
 -66.2%
H
1.3
5.7
|
L
 -68.7%
H
1.3
8
|
L
 -82.8%
H
1.3
10.8
|
L
H
1.3
25.5
|
L
H
1.3
25.5
|
L
H
1.3
25.5
|
Grace Therapeutics Inc. |
|
28.7
|
2.1
|
L
 2.5%
H
2.0
2.2
|
L
 5.6%
H
2.0
2.2
|
L
 -10.3%
H
1.8
2.7
|
L
 -42.9%
H
1.8
4
|
L
 -31.9%
H
1.8
5.0
|
L
 -69.4%
H
1.7
7.4
|
L
 -93.3%
H
1.7
58.6
|
L
 -99.1%
H
1.7
233.2
|
Acurx Pharmaceuticals Inc |
|
8.2
|
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
 5.7%
H
0.4
0.4
|
L
 -9.8%
H
0.3
0.4
|
L
 -58.0%
H
0.3
0.9
|
L
 -82.6%
H
0.3
3.3
|
L
 -90.2%
H
0.3
8.8
|
L
H
0.3
8.8
|
L
H
0.3
8.8
|
Adial Pharmaceuticals Inc |
|
4.5
|
0.7
|
L
 -4.2%
H
0.7
0.7
|
L
 -2.8%
H
0.7
0.8
|
L
 -6.8%
H
0.6
0.8
|
L
 -28.1%
H
0.6
1.3
|
L
 -68.2%
H
0.6
3
|
L
 -98.4%
H
0.6
52
|
L
 -98.2%
H
0.6
127
|
L
H
0.6
236
|
Adverum Biotechnologies Inc |
|
61.2
|
2.9
|
L
 -1.7%
H
2.7
3.0
|
L
 -14.6%
H
2.7
3.7
|
L
 -40.2%
H
2.7
5.7
|
L
 -32.3%
H
2.7
5.7
|
L
 -73.7%
H
2.7
11.9
|
L
 -97.4%
H
2.7
297
|
L
 -99.8%
H
2.7
2698
|
L
 -99.9%
H
2.7
4160
|
Aeterna Zentaris Inc. |
|
8.9
|
2.8
|
L
 0.4%
H
2.8
2.8
|
L
 -0.7%
H
2.8
3.2
|
L
 -15.0%
H
2.3
4.6
|
L
 -5.7%
H
2.0
4.6
|
L
 44.4%
H
2.0
11.1
|
L
 -64.3%
H
1.4
11.1
|
L
 -86.5%
H
1.4
90.5
|
L
 -99.8%
H
1.4
1680
|
Agios Pharmaceuticals Inc |
|
1,584.8
|
27.7
|
L
 1.9%
H
27.0
28.4
|
L
 3.6%
H
26.2
28.4
|
L
 -11.4%
H
23.4
32.9
|
L
 -14.7%
H
23.4
36.2
|
L
 -6.0%
H
23.4
62.6
|
L
 8.2%
H
16.8
62.6
|
L
 -39.1%
H
16.8
62.6
|
L
 -74.3%
H
16.8
126.4
|
Akebia Therapeutics Inc. |
|
538.1
|
2.1
|
L
 8.4%
H
1.9
2.1
|
L
 24.9%
H
1.7
2.1
|
L
 -19.2%
H
1.5
2.9
|
L
 -0.5%
H
1.5
2.9
|
L
 48.2%
H
0.8
2.9
|
L
 338.3%
H
0.2
2.9
|
L
 -72.4%
H
0.2
13.7
|
L
 -75.2%
H
0.2
20.3
|
Akero Therapeutics Inc |
|
2,996.1
|
37.6
|
L
 0.5%
H
36.7
37.9
|
L
 5.5%
H
35.9
39.1
|
L
 -13.6%
H
31.8
46.1
|
L
 49.7%
H
24.7
58.4
|
L
 83.5%
H
17.9
58.4
|
L
 231.3%
H
7.5
58.4
|
L
 83.0%
H
7.5
58.4
|
L
H
7.5
58.4
|
Aligos Therapeutics Inc |
|
28.6
|
4.7
|
L
 2.4%
H
4.4
4.8
|
L
 14.7%
H
4.1
5.7
|
L
 -56.5%
H
3.8
12.2
|
L
 -86.3%
H
3.8
34.4
|
L
 -76.4%
H
3.8
46.3
|
L
 -87.2%
H
3.8
60.3
|
L
H
3.8
937.8
|
L
H
3.8
937.8
|
Alkermes plc |
|
4,450.6
|
27
|
L
 -0.7%
H
27.0
27.5
|
L
H
26.8
28.0
|
L
 -21.4%
H
25.6
35.4
|
L
 -8.4%
H
25.6
36.5
|
L
 13.6%
H
22.9
36.5
|
L
 -6.6%
H
21.8
36.5
|
L
 65.0%
H
13.0
36.5
|
L
 -57.0%
H
12.0
80.7
|
Allakos Inc |
|
29.8
|
0.3
|
L
 3.1%
H
0.3
0.3
|
L
 3.1%
H
0.3
0.3
|
L
 26.9%
H
0.2
0.3
|
L
 -61.6%
H
0.2
1.3
|
L
 -68.9%
H
0.2
1.6
|
L
 -93.2%
H
0.2
8.7
|
L
 -99.5%
H
0.2
158.0
|
L
H
0.2
158.0
|
Allarity Therapeutics Inc |
|
16.0
|
0.9
|
L
 17.5%
H
0.8
1.0
|
L
 28.8%
H
0.7
1.0
|
L
 10.6%
H
0.6
1.2
|
L
 -10.5%
H
0.6
2.0
|
L
 -39.0%
H
0.1
4.0
|
L
 -100.0%
H
0.1
94640
|
L
H
0.1
509600
|
L
H
0.1
509600
|
Alnylam Pharmaceuticals Inc |
|
30,358.3
|
234.6
|
L
 1.8%
H
229.0
235.1
|
L
 -1.4%
H
225.8
242.2
|
L
 -4.0%
H
205.9
300.9
|
L
 -4.8%
H
205.9
300.9
|
L
 61.6%
H
142.0
304.4
|
L
 49.7%
H
117.6
304.4
|
L
 69.4%
H
117.6
304.4
|
L
 100.5%
H
31.4
304.4
|
Rein Therapeutics Inc. |
|
37.4
|
1.7
|
L
 3.0%
H
1.6
1.7
|
L
 -0.6%
H
1.6
1.8
|
L
 -9.1%
H
1.4
2.1
|
L
 -15%
H
1.4
3.5
|
L
 -66%
H
1.4
5.4
|
L
 -84.1%
H
1.0
11.6
|
L
 -84.4%
H
1.0
49.4
|
L
H
1.0
309.6
|
Alzamend Neuro Inc |
|
4.4
|
0.7
|
L
 -5.6%
H
0.7
0.7
|
L
 -13.0%
H
0.7
0.8
|
L
 -28.7%
H
0.7
1.1
|
L
 -42.2%
H
0.6
1.2
|
L
 -2.9%
H
0.4
15.1
|
L
 -95.5%
H
0.4
22.5
|
L
H
0.4
503.3
|
L
H
0.4
503.3
|
Amylyx Pharmaceuticals Inc |
|
352.6
|
4.0
|
L
 4.2%
H
3.8
4.1
|
L
 9.0%
H
3.7
4.1
|
L
 9.3%
H
3.1
4.1
|
L
 10.6%
H
2.6
4.1
|
L
 101.0%
H
1.6
7.3
|
L
 -62.3%
H
1.6
41.9
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
Amphastar Pharmaceuticals Inc |
|
1,109.2
|
23.4
|
L
 1.6%
H
23.1
23.6
|
L
 -3.4%
H
22.6
24.9
|
L
 -14.7%
H
22.6
29.3
|
L
 -34.6%
H
22.6
37.7
|
L
 -39.6%
H
22.6
54.0
|
L
 -39.2%
H
22.6
67.7
|
L
 42.9%
H
15.8
67.7
|
L
 54.5%
H
10.5
67.7
|
Anebulo Pharmaceuticals Inc |
|
41.5
|
1.0
|
L
 -2.9%
H
1.0
1.1
|
L
 3.1%
H
0.9
1.1
|
L
 -42.9%
H
0.9
2.2
|
L
 -36.5%
H
0.9
2.2
|
L
 -64.6%
H
0.8
3.2
|
L
 -81.6%
H
0.8
7
|
L
H
0.8
9.3
|
L
H
0.8
9.3
|
Annexon Inc |
|
160.2
|
1.5
|
L
 2.1%
H
1.4
1.5
|
L
 -2.0%
H
1.4
1.7
|
L
 -41.6%
H
1.3
2.8
|
L
 -65.2%
H
1.3
4.4
|
L
 -67.1%
H
1.3
7.9
|
L
 -30.8%
H
1.3
8.4
|
L
H
1.3
38.0
|
L
H
1.3
38.0
|
Apollomics Inc - Ordinary ... |
|
6.6
|
6.0
|
L
 1.0%
H
5.6
6
|
L
 0.2%
H
4.7
6.4
|
L
 -25.3%
H
4.7
11.6
|
L
 -37.8%
H
4.7
11.6
|
L
 -88.3%
H
0.1
53
|
L
 -99.4%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
Apellis Pharmaceuticals Inc |
|
2,284.4
|
18.2
|
L
 0.2%
H
18.1
18.6
|
L
 -6.3%
H
18
19.7
|
L
 -25.4%
H
17.5
25.6
|
L
 -39.2%
H
17.5
31.2
|
L
 -61.7%
H
17.5
51.0
|
L
 -64.6%
H
17.5
94.8
|
L
 -47.6%
H
17.5
94.8
|
L
H
11.5
94.8
|
Applied Therapeutics Inc |
|
46.7
|
0.3
|
L
 10%
H
0.3
0.4
|
L
 -10.8%
H
0.3
0.4
|
L
 -36.5%
H
0.3
0.6
|
L
 -49.2%
H
0.3
0.8
|
L
 -93.0%
H
0.3
10.6
|
L
 -83.5%
H
0.3
10.6
|
L
 -99.2%
H
0.3
52.0
|
L
H
0.3
57.4
|
Aptorum Group Ltd - Ordina... |
|
5.9
|
0.8
|
L
 -9.8%
H
0.8
0.9
|
L
 5.1%
H
0.8
1.3
|
L
 -13.5%
H
0.7
1.3
|
L
 -27.8%
H
0.7
1.8
|
L
 -84.5%
H
0.5
7.5
|
L
 -94.3%
H
0.5
17.5
|
L
 -97.7%
H
0.5
142.3
|
L
H
0.5
332.8
|
Aprea Therapeutics Inc |
|
8.2
|
1.5
|
L
 -2.6%
H
1.5
1.5
|
L
 -3.2%
H
1.5
1.7
|
L
 -36.7%
H
1.5
2.7
|
L
 -61.0%
H
1.5
4.7
|
L
 -73.3%
H
1.5
5.9
|
L
 -95.2%
H
1.5
32.8
|
L
 -99.8%
H
1.5
822.3
|
L
H
1.5
1062.2
|
Aptose Biosciences Inc |
|
4.8
|
1.9
|
L
 -6.5%
H
1.9
1.9
|
L
 -8.8%
H
1.7
2.4
|
L
 -50.3%
H
1.1
4.0
|
L
 -70.9%
H
0.1
7.8
|
L
 -95.1%
H
0.1
38.6
|
L
 -99.7%
H
0.1
553.5
|
L
 -99.9%
H
0.1
4050
|
L
 -99.9%
H
0.1
4163.6
|
Aquestive Therapeutics Inc |
|
248.2
|
2.5
|
L
 0.4%
H
2.5
2.6
|
L
 1.6%
H
2.4
2.6
|
L
 -8.7%
H
2.2
3.4
|
L
 -19.0%
H
2.2
3.6
|
L
 -44.2%
H
2.2
5.8
|
L
 31.4%
H
0.6
6.2
|
L
 -30.9%
H
0.6
9.5
|
L
H
0.6
20.7
|
Arcturus Therapeutics Hold... |
|
285.6
|
10.5
|
L
 2.2%
H
10.1
10.7
|
L
 8.6%
H
9.5
11
|
L
 -23.3%
H
8.0
13.9
|
L
 -37.3%
H
8.0
19.3
|
L
 -60.0%
H
8.0
45
|
L
 -58.3%
H
8.0
45
|
L
 -40.4%
H
8.0
129.7
|
L
 -73.2%
H
4.1
129.7
|
Ardelyx Inc |
|
1,148.9
|
4.8
|
L
 4.8%
H
4.6
4.8
|
L
 8.1%
H
4.4
4.8
|
L
 -9.4%
H
4.0
5.6
|
L
 -3.8%
H
4.0
6.6
|
L
 -25.2%
H
4.0
9.3
|
L
 502.5%
H
0.5
10.1
|
L
 -31.5%
H
0.5
10.1
|
L
 -61.4%
H
0.5
22.5
|
Arcutis Biotherapeutics Inc |
|
1,543.5
|
13.0
|
L
 0.4%
H
12.8
13.9
|
L
 3.3%
H
12.5
13.9
|
L
 -18.0%
H
11.9
17.8
|
L
 2.6%
H
11.1
17.8
|
L
 37.7%
H
7.0
17.8
|
L
 -35.3%
H
1.8
27.4
|
L
 -52.3%
H
1.8
39.9
|
L
H
1.8
40.9
|
Artelo Biosciences Inc |
|
3.1
|
1.0
|
L
 -2.1%
H
0.9
1.0
|
L
 15.9%
H
0.9
1.4
|
L
 3.3%
H
0.8
1.4
|
L
 -17.4%
H
0.8
1.6
|
L
 -25.8%
H
0.8
1.6
|
L
 -83.8%
H
0.8
7.2
|
L
 -94.5%
H
0.8
55.1
|
L
H
0.8
324
|
Assembly Biosciences Inc |
|
75.3
|
10.0
|
L
 0.3%
H
9.7
10.0
|
L
 10.5%
H
9.4
10.4
|
L
 -10.9%
H
7.8
11.8
|
L
 -30.8%
H
7.8
15.0
|
L
 -24.8%
H
7.8
19.9
|
L
 -56.9%
H
7.7
29.0
|
L
 -95.2%
H
7.7
334.1
|
L
 -95.7%
H
7.7
808.3
|
ASP Isotopes Inc |
|
420.9
|
5.8
|
L
 2.6%
H
5.3
6.0
|
L
 -2.5%
H
5.3
6.8
|
L
 42.1%
H
3.9
6.8
|
L
 3.2%
H
3.7
7
|
L
 89%
H
1.9
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
Assertio Holdings Inc |
|
58.4
|
0.6
|
L
 -1.6%
H
0.6
0.6
|
L
 -1.6%
H
0.6
0.7
|
L
 -15.3%
H
0.5
0.8
|
L
 -26.5%
H
0.5
0.9
|
L
 -18.7%
H
0.5
1.8
|
L
 -76.4%
H
0.5
8.0
|
L
 -83.4%
H
0.5
8.0
|
L
 -99.4%
H
0.5
135.0
|
ATAI Life Sciences N.V. |
|
291.5
|
1.5
|
L
 3.5%
H
1.4
1.5
|
L
 14.0%
H
1.3
1.5
|
L
 8.9%
H
1.2
1.7
|
L
 0.7%
H
1.2
2.6
|
L
 -23.0%
H
1.0
2.6
|
L
 -71.2%
H
1.0
5.3
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
180 Life Sciences Corp |
|
3.9
|
0.9
|
L
 2.3%
H
0.8
0.9
|
L
 5.9%
H
0.8
0.9
|
L
 -15.9%
H
0.7
1.2
|
L
 -42.3%
H
0.7
1.7
|
L
 -50.8%
H
0.7
17.8
|
L
 -99.9%
H
0.7
927.2
|
L
 -100.0%
H
0.7
4957.1
|
L
H
0.7
4957.1
|
Atossa Therapeutics Inc |
|
80.1
|
0.6
|
L
 3.3%
H
0.6
0.6
|
L
 -4.6%
H
0.6
0.7
|
L
 -13.9%
H
0.6
0.8
|
L
 -25.3%
H
0.6
1.0
|
L
 -56.3%
H
0.6
1.8
|
L
 -44.1%
H
0.5
2.3
|
L
 -70.0%
H
0.5
9.8
|
L
 -99.8%
H
0.5
324
|
Atara Biotherapeutics Inc |
|
36.1
|
6.2
|
L
 5.7%
H
5.6
6.2
|
L
 11.6%
H
5.4
6.2
|
L
 -12.1%
H
5
7.2
|
L
 -6.1%
H
5
11.1
|
L
 -64.3%
H
0.4
19
|
L
 -96.8%
H
0.4
233.5
|
L
 -97.2%
H
0.4
705
|
L
 -99.5%
H
0.4
1639
|
Avenue Therapeutics Inc |
|
0.8
|
0.3
|
L
 -7.1%
H
0.3
0.3
|
L
H
0.3
0.3
|
L
 -38.1%
H
0.3
0.4
|
L
 -86.0%
H
0.3
2.1
|
L
 -100.0%
H
0.3
774.6
|
L
 -100.0%
H
0.3
93656.3
|
L
 -100.0%
H
0.3
1041170.6
|
L
H
0.3
1041170.6
|
Astria Therapeutics Inc |
|
228.0
|
4.0
|
L
 1.5%
H
3.9
4.2
|
L
H
3.9
4.4
|
L
 -37.8%
H
3.6
6.6
|
L
 -46.1%
H
3.6
8.0
|
L
 -61.7%
H
3.6
12.9
|
L
 -35.5%
H
2.4
16.9
|
L
 -87.6%
H
2.4
51.5
|
L
H
2.4
1017.6
|
Atea Pharmaceuticals Inc |
|
254.0
|
3.0
|
L
 -1%
H
3.0
3.2
|
L
 9.6%
H
2.7
3.2
|
L
 -6.3%
H
2.6
3.3
|
L
 -11.9%
H
2.6
3.4
|
L
 -19.7%
H
2.6
4.1
|
L
 -52.1%
H
2.6
9.8
|
L
H
2.6
94.2
|
L
H
2.6
94.2
|
Avalo Therapeutics Inc |
|
47.1
|
4.4
|
L
 -4.8%
H
4.3
5.0
|
L
 -10%
H
4.3
5.9
|
L
 -43.2%
H
4.3
9.7
|
L
 -34.7%
H
4.3
11.2
|
L
 -63.3%
H
4.3
17.5
|
L
 -40.1%
H
0.0
34.5
|
L
 -86.9%
H
0.0
54
|
L
H
0.0
91.8
|
Aytu BioPharma Inc |
|
6.2
|
1.0
|
L
 -1.0%
H
1.0
1.0
|
L
 -2.9%
H
1.0
1.1
|
L
 -14.4%
H
1.0
1.4
|
L
 -41.3%
H
1.0
1.8
|
L
 -63.8%
H
1.0
3.5
|
L
 -94.5%
H
1.0
21
|
L
 -99.6%
H
1.0
426
|
L
 -100.0%
H
1.0
11336448
|
Adagene Inc - ADR |
|
72.1
|
1.5
|
L
 -3.2%
H
1.5
1.7
|
L
H
1.5
1.9
|
L
 -15.5%
H
1.3
1.9
|
L
 -16.9%
H
1.3
2.3
|
L
 -42.1%
H
1.3
3.6
|
L
 -58.2%
H
0.9
4.4
|
L
H
0.9
31.8
|
L
H
0.9
31.8
|
Addex Therapeutics Ltd - ADR |
|
8.0
|
7.5
|
L
 0.9%
H
7.3
7.5
|
L
 3.0%
H
6.7
8.1
|
L
 2.7%
H
6.5
8.1
|
L
 -5.9%
H
6.5
9.8
|
L
 -64.2%
H
6.5
20.6
|
L
 -92.5%
H
5
109
|
L
 -95.6%
H
5
750.4
|
L
H
5
750.4
|
Amarin Corp - ADR |
|
188.7
|
9.1
|
L
 -2.7%
H
8.8
9.3
|
L
 -2.0%
H
8.3
10.1
|
L
 2018.6%
H
0.4
10.1
|
L
 1526.8%
H
0.4
10.1
|
L
 947.1%
H
0.4
10.1
|
L
 191.1%
H
0.4
10.1
|
L
 39.9%
H
0.4
10.1
|
L
 291.0%
H
0.4
26.1
|
Ascendis Pharma A/S - ADR |
|
9,923.6
|
165.1
|
L
 4.4%
H
155.7
165.4
|
L
 9.3%
H
151.0
165.4
|
L
 0.2%
H
124.1
169
|
L
 28.8%
H
118.0
169.4
|
L
 17.2%
H
111.1
169.4
|
L
 54.0%
H
61.6
169.4
|
L
 27.9%
H
61.6
184.0
|
L
 744.7%
H
11.9
184.0
|
Alterity Therapeutics Ltd ... |
|
51.8
|
3.5
|
L
 2.9%
H
3.3
3.5
|
L
 11.5%
H
3.1
3.5
|
L
 -8.6%
H
2.5
4.0
|
L
 2.3%
H
2.5
5.9
|
L
 63.6%
H
1
5.9
|
L
 -55.1%
H
1
8.5
|
L
 -44.4%
H
1
51.5
|
L
 -94.8%
H
1
111
|
Avadel Pharmaceuticals plc... |
|
775.9
|
8.0
|
L
 -1.5%
H
7.8
8.2
|
L
 4.6%
H
7.5
8.2
|
L
 -7.0%
H
6.4
8.8
|
L
 3.6%
H
6.4
9.3
|
L
 -53.8%
H
6.4
19.1
|
L
 21.1%
H
1.1
19.1
|
L
 -14.0%
H
1.1
19.1
|
L
 -49.5%
H
1.0
26.1
|
Astrazeneca plc - ADR |
|
209,553.5
|
67.6
|
L
 0.8%
H
67.1
68.2
|
L
 2.0%
H
66.7
68.4
|
L
 -12.3%
H
61.2
77.0
|
L
 1.5%
H
61.2
78.4
|
L
 -1.1%
H
61.2
87.7
|
L
 -1.5%
H
52.7
87.7
|
L
 35.1%
H
46.5
87.7
|
L
 89.5%
H
25.6
87.7
|
Biofrontera Inc |
|
7.5
|
0.9
|
L
 1.2%
H
0.8
0.9
|
L
 1.2%
H
0.8
0.9
|
L
 -14.1%
H
0.7
1.1
|
L
 -22.7%
H
0.7
1.2
|
L
 -49.1%
H
0.7
2.2
|
L
 -98.9%
H
0.6
86
|
L
H
0.6
292.6
|
L
H
0.6
292.6
|
Biomea Fusion Inc |
|
63.5
|
1.7
|
L
 6.3%
H
1.6
1.8
|
L
 -3.4%
H
1.5
1.8
|
L
 -33.2%
H
1.5
3.1
|
L
 -57.5%
H
1.5
4.6
|
L
 -84.9%
H
1.5
13.4
|
L
 -59.7%
H
1.5
43.7
|
L
H
1.5
43.7
|
L
H
1.5
43.7
|
Bolt Biotherapeutics Inc |
|
13.4
|
0.4
|
L
 6.1%
H
0.3
0.4
|
L
 9.4%
H
0.3
0.4
|
L
 -14.6%
H
0.3
0.5
|
L
 -31.4%
H
0.3
0.6
|
L
 -69.3%
H
0.3
1.3
|
L
 -84.5%
H
0.3
2.7
|
L
H
0.3
43.1
|
L
H
0.3
43.1
|
BeyondSpring Inc |
|
52.8
|
1.3
|
L
 4.0%
H
1.3
1.3
|
L
 19.1%
H
1.1
1.3
|
L
 -25.1%
H
1.0
1.7
|
L
 -23.8%
H
1.0
1.9
|
L
 -27.2%
H
1.0
3.6
|
L
 -34.5%
H
0.5
4
|
L
 -89.3%
H
0.5
33
|
L
H
0.5
48.5
|
Biodexa Pharmaceuticals Pl... |
|
3.7
|
1.4
|
L
 -2.1%
H
1.4
1.5
|
L
 -19.2%
H
1.3
1.8
|
L
 -29.2%
H
1.1
2.7
|
L
 -66.6%
H
1.1
9.2
|
L
 -99.7%
H
1.1
1849.9
|
L
 -100.0%
H
1.1
1040000
|
L
 -100.0%
H
1.1
7070000
|
L
H
1.1
398544219.1
|
Bioline Rx Ltd - ADR |
|
10.7
|
2.9
|
L
 4.7%
H
2.7
2.9
|
L
 4.7%
H
2.7
3.0
|
L
 -9.4%
H
2.3
3.6
|
L
 -29.1%
H
0.1
4.8
|
L
 -88.8%
H
0.1
35.6
|
L
 -95.1%
H
0.1
101.2
|
L
 -95.9%
H
0.1
253.6
|
L
 -99.8%
H
0.1
1680
|
Belite Bio Inc - ADR |
|
1,820.7
|
56.4
|
L
 -1.5%
H
55.5
58.0
|
L
 -0.4%
H
55.5
60.2
|
L
 -17.5%
H
49
68.6
|
L
 0.3%
H
49
71.0
|
L
 63.0%
H
32.5
86.5
|
L
H
6
86.5
|
L
H
6
86.5
|
L
H
6
86.5
|
Neuphoria Therapeutics Inc. |
|
9.0
|
5.1
|
L
 0.6%
H
5.0
5.2
|
L
 3.8%
H
4.9
5.3
|
L
 4.9%
H
4.5
6.1
|
L
 63.2%
H
3.1
12.6
|
L
 424.5%
H
0.2
12.6
|
L
 -41.3%
H
0.2
12.6
|
L
H
0.2
22
|
L
H
0.2
22
|
Capricor Therapeutics Inc |
|
513.9
|
11.3
|
L
 16.7%
H
10.2
11.3
|
L
 21.1%
H
9.2
11.3
|
L
 -3.1%
H
8.1
14.8
|
L
 -17.9%
H
8.1
16.5
|
L
 122.8%
H
3.5
23.4
|
L
 245.1%
H
2.7
23.4
|
L
 616.6%
H
1.6
23.4
|
L
 -82.9%
H
0.9
83.1
|
CASI Pharmaceuticals Inc |
|
30.1
|
1.9
|
L
 0.5%
H
1.9
2.2
|
L
 -0.5%
H
1.9
2.2
|
L
 -20.2%
H
1.9
2.5
|
L
 -26.0%
H
1.9
2.9
|
L
 -13.4%
H
1.9
7.7
|
L
 -67.7%
H
1.5
8.5
|
L
 -88.9%
H
1.5
39
|
L
 -87.0%
H
1.5
88.9
|
Cullinan Oncology Inc |
|
461.7
|
7.9
|
L
 3.7%
H
7.4
8.0
|
L
 2.3%
H
7.4
8.1
|
L
 -11.7%
H
6.9
8.9
|
L
 -23.1%
H
6.9
11.9
|
L
 -56.3%
H
6.9
30.2
|
L
 -26.8%
H
6.9
30.2
|
L
H
6.9
59.9
|
L
H
6.9
59.9
|
Coherus Biosciences Inc |
|
129.8
|
1.1
|
L
 10.9%
H
1.0
1.1
|
L
 33.3%
H
0.9
1.1
|
L
 25.8%
H
0.7
1.1
|
L
 -19.4%
H
0.7
1.5
|
L
 -44%
H
0.7
2.4
|
L
 -89.3%
H
0.7
14.1
|
L
 -92.8%
H
0.7
22.2
|
L
 -95.6%
H
0.7
38.1
|
Cingulate Inc |
|
15.5
|
4.2
|
L
 1.4%
H
4.0
4.3
|
L
 11.6%
H
3.9
4.6
|
L
 16.5%
H
3.4
4.6
|
L
 -10.9%
H
3.4
5.2
|
L
 381.8%
H
0.2
20.8
|
L
 157.0%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
Checkpoint Therapeutics Inc |
|
338.4
|
4.0
|
L
H
4.0
4.0
|
L
 1.3%
H
4.0
4.0
|
L
 0.8%
H
3.9
4.1
|
L
 27.0%
H
2.4
4.1
|
L
 152.5%
H
1.4
4.5
|
L
 -70.7%
H
1.3
14.9
|
L
 -74.4%
H
1.3
53.8
|
L
H
1.3
150
|
Clene Inc |
|
25.9
|
3
|
L
 -0.7%
H
2.9
3.0
|
L
 -1.0%
H
2.8
3.2
|
L
 -32.7%
H
2.6
4.5
|
L
 -37.4%
H
2.6
5.0
|
L
 -54.6%
H
2.6
9.2
|
L
 -94.7%
H
2.6
102.6
|
L
 466.0%
H
0.5
356.4
|
L
H
0.5
356.4
|
Cellectar Biosciences Inc |
|
13.8
|
0.3
|
L
 7.1%
H
0.3
0.3
|
L
 7.1%
H
0.3
0.3
|
L
 -21.1%
H
0.2
0.4
|
L
 25%
H
0.2
0.4
|
L
 -90.1%
H
0.2
3.5
|
L
 -95.3%
H
0.2
6.8
|
L
 -98.1%
H
0.2
29.8
|
L
 -100.0%
H
0.2
3889
|
Clearside Biomedical Inc |
|
66.3
|
0.9
|
L
 -1.2%
H
0.8
0.9
|
L
 13.2%
H
0.8
0.9
|
L
 -11.3%
H
0.7
1.1
|
L
 -7.5%
H
0.7
1.1
|
L
 -34.9%
H
0.7
1.7
|
L
 -55.4%
H
0.7
2.1
|
L
 -60.6%
H
0.7
7.7
|
L
H
0.6
25.1
|
Clearmind Medicine Inc |
|
5.8
|
1.1
|
L
 15.5%
H
1.0
1.2
|
L
 17.9%
H
0.9
1.2
|
L
 -6.7%
H
0.9
1.3
|
L
 -24.8%
H
0.9
1.5
|
L
 -5.1%
H
0.9
2.3
|
L
 -87.6%
H
0.1
15
|
L
 -5.9%
H
0.1
21.9
|
L
H
0.1
21.9
|
Compass Therapeutics Inc |
|
242.0
|
1.8
|
L
 2.9%
H
1.7
1.8
|
L
 2.9%
H
1.6
1.8
|
L
 -24.2%
H
1.3
2.4
|
L
 -32.7%
H
1.3
4.1
|
L
 17.5%
H
0.8
4.1
|
L
 15.9%
H
0.8
5.7
|
L
H
0.8
11
|
L
H
0.8
11
|
Chimerix Inc |
|
801.1
|
8.5
|
L
 -0.1%
H
8.5
8.6
|
L
 0.2%
H
8.5
8.6
|
L
 0.7%
H
8.5
8.6
|
L
 140.6%
H
3.4
8.6
|
L
 818.3%
H
0.8
8.6
|
L
 88.9%
H
0.8
8.6
|
L
 437.1%
H
0.8
11.6
|
L
 -77.8%
H
0.8
58.0
|
Cns Pharmaceuticals Inc |
|
2.4
|
0.8
|
L
H
0.8
0.9
|
L
 -38.8%
H
0.8
1.3
|
L
 -76.9%
H
0.8
4.6
|
L
 -83.9%
H
0.8
9.5
|
L
 -99.8%
H
0.8
800
|
L
 -100.0%
H
0.8
29850
|
L
 -100.0%
H
0.8
334500
|
L
H
0.8
426750
|
Context Therapeutics Inc |
|
75.4
|
0.8
|
L
 -2.3%
H
0.8
0.9
|
L
 7.7%
H
0.8
0.9
|
L
 5%
H
0.6
1.0
|
L
 -16.8%
H
0.6
1.0
|
L
 -40.4%
H
0.6
2.8
|
L
 -48.1%
H
0.5
2.8
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
Cocrystal Pharma Inc |
|
13.3
|
1.3
|
L
H
1.3
1.3
|
L
 2.3%
H
1.2
1.5
|
L
 -17.6%
H
1.1
1.6
|
L
 -33.8%
H
1.1
2.3
|
L
 -12.7%
H
1.1
3.3
|
L
 -79.4%
H
1.1
6.5
|
L
 -87.1%
H
1.1
41.5
|
L
 -99.7%
H
1.1
529.2
|
Collegium Pharmaceutical Inc |
|
867.9
|
27.0
|
L
 0.0%
H
26.9
27.8
|
L
 2.7%
H
26.3
27.8
|
L
 -9.4%
H
23.2
30.8
|
L
 -19.0%
H
23.2
34.1
|
L
 -22.3%
H
23.2
42.3
|
L
 49.3%
H
14.0
42.3
|
L
 38.4%
H
14.0
42.3
|
L
H
7.4
42.3
|
Corcept Therapeutics Inc |
|
6,566.5
|
62.2
|
L
 -3.7%
H
61.9
65.4
|
L
 -9.3%
H
61.9
71.2
|
L
 10.2%
H
53.8
117.3
|
L
 12.5%
H
52.5
117.3
|
L
 174.7%
H
20.8
117.3
|
L
 167.6%
H
17.2
117.3
|
L
 392.4%
H
11.9
117.3
|
L
 944.3%
H
3.2
117.3
|
Cosmos Health Inc |
|
7.9
|
0.3
|
L
H
0.3
0.4
|
L
 -8.1%
H
0.3
0.4
|
L
 -29.2%
H
0.3
0.5
|
L
 -60.5%
H
0.3
1.1
|
L
 -44.3%
H
0.3
1.6
|
L
 -98.8%
H
0.3
62.3
|
L
 -99.4%
H
0.3
225
|
L
 -99.8%
H
0.3
312.5
|
Cumberland Pharmaceuticals... |
|
66.5
|
4.8
|
L
 5.1%
H
4.5
4.8
|
L
 17.2%
H
3.9
4.8
|
L
 -7.4%
H
3.8
5.5
|
L
 88.1%
H
2.1
7.3
|
L
 188.5%
H
1.0
7.3
|
L
 86.7%
H
1.0
7.3
|
L
 19%
H
1.0
7.5
|
L
 -31.9%
H
1.0
8.0
|
Catalyst Pharmaceuticals Inc |
|
2,746.5
|
22.5
|
L
 1.5%
H
22.1
22.7
|
L
 2.1%
H
21.9
23.3
|
L
 2.0%
H
20.4
26.2
|
L
 -1.1%
H
20.2
26.2
|
L
 46.8%
H
14.5
26.2
|
L
 175.3%
H
6.2
26.2
|
L
 391.7%
H
2.9
26.2
|
L
 411.8%
H
0.5
26.2
|
Corbus Pharmaceuticals Hol... |
|
73.8
|
6.0
|
L
 1.9%
H
5.8
6.1
|
L
 -0.2%
H
5.7
6.3
|
L
 -4.7%
H
4.6
6.5
|
L
 -49.4%
H
4.6
12.4
|
L
 -83.5%
H
4.6
61.9
|
L
 -44.7%
H
2.1
61.9
|
L
 -96.6%
H
2.1
293.4
|
L
 -93.7%
H
2.1
323.4
|
Crinetics Pharmaceuticals Inc |
|
2,830.5
|
30.4
|
L
 2.8%
H
29.4
30.6
|
L
 4.5%
H
28.6
30.6
|
L
 -11%
H
24.1
36.5
|
L
 -18.6%
H
24.1
41.5
|
L
 -29.3%
H
24.1
62.5
|
L
 32.6%
H
15.2
62.5
|
L
 98.2%
H
11.6
62.5
|
L
H
10.6
62.5
|
Corvus Pharmaceuticals Inc |
|
220.8
|
3.2
|
L
 0.3%
H
3.2
3.3
|
L
 8.7%
H
3.0
3.4
|
L
 -30.9%
H
2.5
4.8
|
L
 -35.3%
H
2.5
5.7
|
L
 129.8%
H
1.4
10
|
L
 141.8%
H
0.6
10
|
L
 32.8%
H
0.6
10
|
L
H
0.6
22.1
|
CytomX Therapeutics Inc |
|
52.9
|
0.7
|
L
 4.8%
H
0.6
0.7
|
L
 24.5%
H
0.5
0.7
|
L
 10%
H
0.4
0.7
|
L
 -21.4%
H
0.4
1.0
|
L
 -61.9%
H
0.4
5.9
|
L
 -70.1%
H
0.4
5.9
|
L
 -93.0%
H
0.4
15.4
|
L
H
0.4
35
|
CureVac N.V. |
|
702.5
|
3.1
|
L
 -2.5%
H
3.1
3.2
|
L
 -2.2%
H
3.0
3.3
|
L
 3.3%
H
2.5
3.3
|
L
 -23.9%
H
2.5
4.3
|
L
 27.9%
H
2.2
5.3
|
L
 -80.5%
H
2.2
20.1
|
L
H
2.2
151.8
|
L
H
2.2
151.8
|
Cyclacel Pharmaceuticals Inc |
|
47.7
|
0.2
|
L
 4.6%
H
0.2
0.2
|
L
 -4.2%
H
0.2
0.3
|
L
 -23.3%
H
0.2
0.3
|
L
 -36.1%
H
0.2
0.4
|
L
 -87.6%
H
0.2
4
|
L
 -88.4%
H
0.2
4.4
|
L
 -96.3%
H
0.2
19.3
|
L
 -99.9%
H
0.2
256.8
|
Cyclerion Therapeutics Inc |
|
7.0
|
2.8
|
L
 2.6%
H
2.6
2.8
|
L
 7.4%
H
2.5
2.9
|
L
 6.6%
H
2.4
2.9
|
L
 -8.0%
H
2.3
6.3
|
L
 -14.6%
H
1.3
8.4
|
L
 -86.0%
H
1.3
25
|
L
 -96.0%
H
1.3
179.2
|
L
H
1.3
457
|
Cytokinetics Inc |
|
4,705.5
|
39.5
|
L
 0.8%
H
38.4
39.5
|
L
 2.2%
H
37.8
40.2
|
L
 -8.8%
H
32.7
48.4
|
L
 -13.7%
H
32.7
52.8
|
L
 -41.1%
H
32.7
68.8
|
L
 3.2%
H
26.0
110
|
L
 159.1%
H
13.9
110
|
L
 468.1%
H
5.5
110
|
Cellectis - ADR |
|
145.4
|
1.5
|
L
 1.4%
H
1.4
1.5
|
L
 0.7%
H
1.4
1.6
|
L
 14.2%
H
1.1
1.6
|
L
 -2.0%
H
1.1
1.7
|
L
 -41.3%
H
1.1
3.4
|
L
 -64.8%
H
1.0
4.2
|
L
 -88.7%
H
1.0
34.7
|
L
 -95.6%
H
1.0
50
|
Centessa Pharmaceuticals p... |
|
1,638.2
|
12.3
|
L
 4.0%
H
11.9
12.3
|
L
 6.3%
H
11.5
12.8
|
L
 -25.5%
H
9.6
17.1
|
L
 -18.9%
H
9.6
19.1
|
L
 16.8%
H
7.8
19.1
|
L
 41.4%
H
2.9
19.1
|
L
H
2.9
26.9
|
L
H
2.9
26.9
|
Connect Biopharma Holdings... |
|
41.0
|
0.7
|
L
 -10.8%
H
0.7
0.9
|
L
 19.4%
H
0.6
1
|
L
 -7.5%
H
0.5
1
|
L
 -29.5%
H
0.5
1.1
|
L
 -51.3%
H
0.5
2.1
|
L
 -75.3%
H
0.5
3.0
|
L
H
0.5
29.3
|
L
H
0.5
29.3
|
Dare Bioscience Inc |
|
25.7
|
2.9
|
L
 -0.3%
H
2.9
2.9
|
L
 -1.4%
H
2.9
3.0
|
L
 -2.4%
H
2.9
3.0
|
L
 -13.2%
H
2.9
3.4
|
L
 -18.1%
H
0.3
7.6
|
L
 -81.6%
H
0.3
17.6
|
L
 -76.5%
H
0.3
46.2
|
L
 -99.6%
H
0.3
804
|
Day One Biopharmaceuticals... |
|
693.3
|
6.8
|
L
 1.2%
H
6.6
6.9
|
L
 -3.9%
H
6.6
7.4
|
L
 -16.2%
H
6.4
8.6
|
L
 -45.5%
H
6.4
13.5
|
L
 -56.6%
H
6.4
18.1
|
L
 -38.5%
H
5.4
28.4
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
Journey Medical Corp |
|
144.4
|
6.3
|
L
 0.6%
H
6.1
6.3
|
L
 3.7%
H
5.7
6.4
|
L
 17.3%
H
5.3
7.3
|
L
 70.8%
H
3.5
7.3
|
L
 74.6%
H
3.2
7.3
|
L
 31.0%
H
1.0
8.1
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
DiaMedica Therapeutics Inc |
|
151.7
|
3.5
|
L
 2.0%
H
3.4
3.6
|
L
 2.0%
H
3.3
3.9
|
L
 -32.1%
H
3.2
5.5
|
L
 -38%
H
3.2
6.8
|
L
 42.2%
H
2.1
6.8
|
L
 63.1%
H
1.1
6.8
|
L
 2.3%
H
1.1
10.9
|
L
 145.8%
H
1
13.8
|
Dermata Therapeutics Inc |
|
4.0
|
0.7
|
L
 2.8%
H
0.7
0.7
|
L
 -9.9%
H
0.7
0.9
|
L
 -39.2%
H
0.7
2.4
|
L
 -45.1%
H
0.7
2.4
|
L
 114.7%
H
0.3
5.8
|
L
 -96.1%
H
0.2
22.7
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
Durect Corp |
|
23.3
|
0.8
|
L
 4.2%
H
0.7
0.8
|
L
H
0.7
0.8
|
L
 -6.3%
H
0.7
0.9
|
L
 -11.8%
H
0.7
0.9
|
L
 -17.6%
H
0.7
1.9
|
L
 -83.0%
H
0.5
9.7
|
L
 -96.2%
H
0.5
29.6
|
L
 -96.1%
H
0.5
39.5
|
DBV Technologies - ADR |
|
218.1
|
8.0
|
L
 0.9%
H
7.7
8.4
|
L
 9.0%
H
7
8.4
|
L
 69.1%
H
3.9
8.5
|
L
 78.9%
H
3.8
8.5
|
L
 20.7%
H
0.5
8.5
|
L
 -44.2%
H
0.5
34.3
|
L
 -82.2%
H
0.5
73.8
|
L
 -96.8%
H
0.5
505.7
|
Edesa Biotech Inc |
|
15.9
|
2.3
|
L
 -3.4%
H
2.2
2.3
|
L
 0.4%
H
2.2
2.4
|
L
 -5.0%
H
2.1
2.6
|
L
 32.9%
H
1.7
4.5
|
L
 -48.2%
H
1.6
5.6
|
L
 -88.9%
H
1.6
20.6
|
L
 -86.9%
H
1.6
133.7
|
L
 -99.9%
H
1.6
3228.1
|
Eagle Pharmaceuticals Inc |
|
23.3
|
1.8
|
L
 11.1%
H
1.6
1.8
|
L
 50%
H
0.9
1.8
|
L
 38.5%
H
0.8
2
|
L
 176.9%
H
0.4
2
|
L
 -59.8%
H
0
6.4
|
L
 -96.3%
H
0
50.9
|
L
 -96.6%
H
0
58.3
|
L
 -96.8%
H
0
104.2
|
Eledon Pharmaceuticals Inc |
|
179.0
|
3.0
|
L
 -0.3%
H
2.9
3.1
|
L
 1.7%
H
2.9
3.2
|
L
 -15.5%
H
2.6
3.7
|
L
 -25.6%
H
2.6
5.0
|
L
 50.3%
H
1.8
5.4
|
L
 7.6%
H
1.1
5.4
|
L
 -56.3%
H
1.1
27.3
|
L
 -99.8%
H
1.1
2383.0
|
Enanta Pharmaceuticals Inc |
|
108.8
|
5.1
|
L
 3.5%
H
4.8
5.2
|
L
 8.7%
H
4.6
5.3
|
L
 -19.1%
H
4.1
6.5
|
L
 -2.9%
H
4.1
8.8
|
L
 -61.5%
H
4.1
17.2
|
L
 -92.8%
H
4.1
76.6
|
L
 -90.7%
H
4.1
102
|
L
 -85.9%
H
4.1
127.8
|
Entera Bio Ltd |
|
81.3
|
1.8
|
L
 1.7%
H
1.8
1.8
|
L
 5.9%
H
1.6
1.8
|
L
 -8.2%
H
1.5
2.0
|
L
 -23.5%
H
1.5
2.6
|
L
 -20.1%
H
1.4
2.8
|
L
 -35.4%
H
0.5
3.4
|
L
 -9.6%
H
0.5
10.2
|
L
H
0.5
10.2
|
Evolus Inc |
|
686.1
|
10.8
|
L
 6.7%
H
10.3
11.0
|
L
 13.1%
H
9.5
11.0
|
L
 -18.8%
H
8.7
13.7
|
L
 2.7%
H
8.7
17.1
|
L
 -6.7%
H
8.7
17.8
|
L
 -1.1%
H
6.5
17.8
|
L
 143.6%
H
2.9
17.8
|
L
H
2.9
39.5
|
Essa Pharma Inc |
|
79.5
|
1.8
|
L
 1.1%
H
1.7
1.8
|
L
 13.3%
H
1.6
1.9
|
L
 11.9%
H
1.4
1.9
|
L
 2.3%
H
1.4
1.9
|
L
 -73.4%
H
1.4
7.9
|
L
 -73.9%
H
1.4
11.7
|
L
 -55.8%
H
1.4
36
|
L
 -98.8%
H
1.4
245
|
Erasca Inc |
|
328.6
|
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 -6.5%
H
1.1
1.3
|
L
 -19.4%
H
1.0
1.6
|
L
 -37.3%
H
1.0
2.1
|
L
 -35.2%
H
1.0
3.5
|
L
 -86.0%
H
1.0
10.7
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
Esperion Therapeutics Inc. |
|
188.0
|
1.0
|
L
 -1.0%
H
0.9
1
|
L
 -6.9%
H
0.9
1.1
|
L
 -39.9%
H
0.9
1.8
|
L
 -57.0%
H
0.9
2.3
|
L
 -49.2%
H
0.9
3.9
|
L
 -81.1%
H
0.7
8.9
|
L
 -97.5%
H
0.7
53.7
|
L
 -99.1%
H
0.7
121.0
|
89bio Inc |
|
884.7
|
6.1
|
L
 2.9%
H
5.8
6.1
|
L
 9.6%
H
5.6
6.1
|
L
 -29.1%
H
4.2
9.3
|
L
 -4.0%
H
4.2
11.8
|
L
 -31.8%
H
4.2
11.8
|
L
 110.4%
H
2
22.9
|
L
 -73.0%
H
2
42.4
|
L
H
2
47.3
|
Eton Pharmaceuticals Inc |
|
384.6
|
14.3
|
L
 1.9%
H
13.5
14.5
|
L
 15.2%
H
12.3
14.5
|
L
 -2.3%
H
11.1
15.2
|
L
 -0.5%
H
11.1
18.4
|
L
 368.6%
H
3.0
18.4
|
L
 278.4%
H
2.0
18.4
|
L
 240.6%
H
2.0
18.4
|
L
H
2.0
18.4
|
Evoke Pharma Inc |
|
3.2
|
2.2
|
L
H
2.0
2.2
|
L
 -2.3%
H
1.9
2.3
|
L
 -33.0%
H
1.9
3.4
|
L
 -51.1%
H
1.9
5.4
|
L
 -62.6%
H
0.4
12.3
|
L
 -96.0%
H
0.4
201.6
|
L
 -98.9%
H
0.4
873.0
|
L
 -99.8%
H
0.4
1599.8
|
Exelixis Inc |
|
9,973.4
|
36.2
|
L
 0.1%
H
35.7
36.5
|
L
 2.5%
H
35.3
36.7
|
L
 -0.5%
H
32.4
38.4
|
L
 0.0%
H
31.9
40.0
|
L
 60.9%
H
20.1
40.0
|
L
 58.4%
H
14.9
40.0
|
L
 86.2%
H
14.9
40.0
|
L
 1063.7%
H
2.5
40.0
|
Eyenovia Inc |
|
3.1
|
1.1
|
L
 0.9%
H
1.0
1.1
|
L
 13.7%
H
1.0
1.2
|
L
 -34.9%
H
0.9
1.7
|
L
 -78.4%
H
0.0
5.4
|
L
 -97.5%
H
0.0
124.8
|
L
 -99.5%
H
0.0
468
|
L
 -99.6%
H
0.0
617.6
|
L
H
0.0
859.2
|
EyePoint Pharmaceuticals Inc |
|
390.4
|
5.7
|
L
 2.3%
H
5.4
5.7
|
L
 5.6%
H
5.1
5.9
|
L
 -8.5%
H
3.9
6.7
|
L
 -24.1%
H
3.9
9.1
|
L
 -67.5%
H
3.9
21.3
|
L
 -53.8%
H
2.2
31.0
|
L
 -39.2%
H
2.2
31.0
|
L
 -85.8%
H
2.2
58.1
|
Evotec SE - ADR |
|
1,278.4
|
3.6
|
L
 10.1%
H
3.6
3.7
|
L
 13.2%
H
3.3
3.7
|
L
 -1.1%
H
2.8
3.7
|
L
 -12.4%
H
2.8
4.8
|
L
 -49.7%
H
2.8
7.8
|
L
 -73.6%
H
2.8
15.0
|
L
 -72.2%
H
2.8
26.6
|
L
 76.5%
H
1.6
26.6
|
Fortress Biotech Inc |
|
45.2
|
1.5
|
L
 2%
H
1.5
1.6
|
L
 4.8%
H
1.5
1.6
|
L
 -11.1%
H
1.3
1.8
|
L
 -18.2%
H
1.3
2
|
L
 -15.5%
H
1.3
2.9
|
L
 -90.2%
H
1.2
20.0
|
L
 -95.4%
H
1.2
91.5
|
L
 -97.6%
H
1.2
91.5
|
Fennec Pharmaceuticals Inc |
|
140.2
|
5.1
|
L
 -0.4%
H
5.0
5.2
|
L
 1.4%
H
5.0
5.5
|
L
 -22.7%
H
4.7
6.9
|
L
 -8.3%
H
4.7
7.1
|
L
 -46.9%
H
4.0
10.1
|
L
 -17.3%
H
4.0
11.9
|
L
 -27.3%
H
3.8
11.9
|
L
 106.5%
H
0.3
15.0
|
FibroGen Inc |
|
29.3
|
0.3
|
L
 3.6%
H
0.3
0.3
|
L
 3.6%
H
0.3
0.3
|
L
 -17.1%
H
0.2
0.4
|
L
 -49.1%
H
0.2
0.9
|
L
 -75.2%
H
0.2
1.7
|
L
 -97.3%
H
0.2
25.7
|
L
 -99.3%
H
0.2
57.2
|
L
 -99.0%
H
0.2
68.6
|
Q32 Bio Inc. |
|
25.9
|
2.1
|
L
 14.6%
H
1.8
2.1
|
L
 1.9%
H
1.8
2.2
|
L
 -0.9%
H
1.4
2.3
|
L
 -35.4%
H
1.4
3.6
|
L
 -91.3%
H
1.4
53.8
|
L
 -94.3%
H
1.4
59.4
|
L
 -99.1%
H
1.4
312.1
|
L
H
1.4
572.4
|
Amicus Therapeutics Inc |
|
2,098.4
|
6.8
|
L
 1.9%
H
6.6
6.9
|
L
 5.4%
H
6.5
6.9
|
L
 -23.9%
H
6.2
9.3
|
L
 -27.4%
H
6.2
10
|
L
 -33.9%
H
6.2
12.7
|
L
 -13.9%
H
5.9
14.6
|
L
 -40.6%
H
5.9
25.4
|
L
 -43.1%
H
4.4
25.4
|
Fulcrum Therapeutics Inc |
|
177.6
|
3.3
|
L
 7.5%
H
3.1
3.3
|
L
 22.3%
H
2.7
3.3
|
L
 8.9%
H
2.3
3.3
|
L
 -16.9%
H
2.3
4.3
|
L
 -53.4%
H
2.3
10.1
|
L
 -75.2%
H
2.3
15
|
L
 -70.0%
H
2.3
33.1
|
L
H
2.3
33.1
|
Generation Bio Co |
|
26.1
|
0.4
|
L
 11.4%
H
0.3
0.4
|
L
H
0.3
0.4
|
L
 -30.4%
H
0.3
0.6
|
L
 -59.0%
H
0.3
1.0
|
L
 -86.0%
H
0.3
4.3
|
L
 -95.1%
H
0.3
8.7
|
L
H
0.3
55.7
|
L
H
0.3
55.7
|
GH Research PLC |
|
564.5
|
9.1
|
L
 4.6%
H
8.7
9.2
|
L
 1.1%
H
8.5
9.4
|
L
 -14.2%
H
8.0
13.2
|
L
 2.5%
H
8.0
20.5
|
L
 -18.7%
H
6
20.5
|
L
 -52.3%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
Galmed Pharmaceuticals Ltd |
|
3.1
|
1.4
|
L
 1.5%
H
1.3
1.4
|
L
 4.6%
H
1.3
1.5
|
L
 -45.0%
H
1.2
2.4
|
L
 -52.4%
H
1.2
3.5
|
L
 -69.6%
H
0.2
13.6
|
L
 -99.5%
H
0.2
307.8
|
L
 -99.8%
H
0.2
1132.2
|
L
 -99.9%
H
0.2
4870.8
|
Galecto Inc |
|
3.2
|
2.4
|
L
 2.1%
H
2.4
2.5
|
L
 4.7%
H
2.3
2.6
|
L
 -43.4%
H
2.0
7.3
|
L
 -52.6%
H
2.0
7.3
|
L
 237.5%
H
0.5
14.8
|
L
 12.0%
H
0.5
14.8
|
L
H
0.5
18.0
|
L
H
0.5
18.0
|
GlycoMimetics Inc |
|
14.2
|
0.2
|
L
H
0.2
0.2
|
L
 10%
H
0.2
0.2
|
L
 -18.5%
H
0.2
0.3
|
L
 -15.4%
H
0.2
0.4
|
L
 -89.8%
H
0.1
2.2
|
L
 -76.1%
H
0.1
4.2
|
L
 -91.4%
H
0.1
5.2
|
L
 -97.4%
H
0.1
26.1
|
Genelux Corp |
|
98.9
|
2.6
|
L
 2.3%
H
2.5
2.7
|
L
 6.9%
H
2.3
2.7
|
L
 -28.9%
H
2.0
4.1
|
L
 6.9%
H
2.0
5.9
|
L
 -31.9%
H
1.6
5.9
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
Genprex Inc |
|
5.8
|
0.2
|
L
 -7.7%
H
0.2
0.3
|
L
 -11.1%
H
0.2
0.3
|
L
 -29.4%
H
0.2
0.4
|
L
 -66.7%
H
0.2
0.8
|
L
 -89.2%
H
0.2
4.1
|
L
 -86.9%
H
0.2
8.0
|
L
 -88.5%
H
0.2
8.0
|
L
H
0.2
19.5
|
Gossamer Bio Inc |
|
190.9
|
0.8
|
L
 1.2%
H
0.8
0.9
|
L
 2.4%
H
0.8
0.9
|
L
 -40.9%
H
0.8
1.4
|
L
 -12.5%
H
0.8
1.6
|
L
 3.7%
H
0.5
1.6
|
L
 -90.4%
H
0.5
15.2
|
L
 -92.7%
H
0.5
16.8
|
L
H
0.5
27.2
|
Galera Therapeutics Inc |
|
1.5
|
0.0
|
L
 -33.3%
H
0.0
0.0
|
L
H
0.0
0.0
|
L
 -50%
H
0.0
0.0
|
L
 -50%
H
0.0
0.1
|
L
 -89.5%
H
0.0
0.2
|
L
 -99.0%
H
0.0
3.6
|
L
 -99.8%
H
0.0
15
|
L
H
0.0
19.5
|
GT Biopharma Inc |
|
5.8
|
2.3
|
L
 0.9%
H
2.2
2.3
|
L
 1.8%
H
2.2
2.4
|
L
 -7.7%
H
2.1
2.5
|
L
 -5.0%
H
2.0
3.1
|
L
 -40.3%
H
1.7
10.7
|
L
 -5.0%
H
0.2
10.7
|
L
 -7.7%
H
0.2
19.7
|
L
 -100.0%
H
0.2
50362.5
|
Genmab - ADR |
|
12,541.8
|
20.0
|
L
 2.5%
H
19.4
20.2
|
L
 6.5%
H
19.1
20.2
|
L
 -0.8%
H
17.2
20.4
|
L
 -3.7%
H
17.2
24.3
|
L
 -29.3%
H
17.2
30.4
|
L
 -45.0%
H
17.2
47.5
|
L
 -12.8%
H
17.2
49.1
|
L
 170.1%
H
7.6
49.1
|
Genfit - ADR |
|
175.2
|
3.5
|
L
H
3.5
3.5
|
L
 3.5%
H
3.4
3.7
|
L
 -3.6%
H
2.6
3.7
|
L
 1.2%
H
2.6
4.3
|
L
 -2.2%
H
2.6
6.4
|
L
 -13.3%
H
2.6
6.4
|
L
 -80.2%
H
2.6
22.5
|
L
H
2.6
26.3
|
Genenta Science SpA - ADR |
|
71.0
|
3.9
|
L
H
3.6
4.0
|
L
 6.3%
H
3.5
4.2
|
L
 2.1%
H
3.3
4.4
|
L
 3.2%
H
3.3
4.8
|
L
 -1.0%
H
2.2
7.3
|
L
 -38.4%
H
2.2
9.3
|
L
H
2.2
13.1
|
L
H
2.2
13.1
|
Grifols SA - ADR - Level III |
|
4,817.3
|
7.1
|
L
 0.7%
H
7.0
7.2
|
L
 4.7%
H
6.8
7.2
|
L
 -12.6%
H
6.2
8.2
|
L
 -2.6%
H
6.2
8.8
|
L
 8.3%
H
5.8
10.0
|
L
 -33.2%
H
5.3
13.3
|
L
 -66.2%
H
5.3
21.9
|
L
 -58.6%
H
5.3
25.7
|
Hepion Pharmaceuticals Inc |
|
3.5
|
0.3
|
L
 -5.9%
H
0.3
0.3
|
L
 -23.8%
H
0.3
0.4
|
L
 -59.0%
H
0.3
1.0
|
L
 -98.6%
H
0.3
22
|
L
 -99.7%
H
0.3
110
|
L
 -100.0%
H
0.3
1192.7
|
L
 -100.0%
H
0.3
4830
|
L
 -100.0%
H
0.3
3516800
|
Hoth Therapeutics Inc |
|
10.4
|
0.8
|
L
 2.6%
H
0.8
0.8
|
L
 -1.3%
H
0.7
0.9
|
L
 -25.5%
H
0.7
1.1
|
L
 -47.3%
H
0.7
1.7
|
L
 -33.1%
H
0.6
3.8
|
L
 -95.1%
H
0.6
18.2
|
L
 -99.0%
H
0.6
124
|
L
H
0.6
347
|
Werewolf Therapeutics Inc |
|
41.2
|
0.9
|
L
 8.2%
H
0.8
0.9
|
L
 29.6%
H
0.7
0.9
|
L
 -20.7%
H
0.6
1.2
|
L
 -30.8%
H
0.6
1.6
|
L
 -84.3%
H
0.6
6.9
|
L
 -78.0%
H
0.6
8.2
|
L
H
0.6
24.0
|
L
H
0.6
24.0
|
Harmony Biosciences Holdin... |
|
1,633.2
|
28.5
|
L
 1.9%
H
28.0
28.5
|
L
 -2.4%
H
27.6
29.7
|
L
 -18.2%
H
26.5
36.0
|
L
 -27.1%
H
26.5
40.9
|
L
 -2.0%
H
26.5
41.6
|
L
 -43.6%
H
18.6
62.1
|
L
H
18.6
62.1
|
L
H
18.6
62.1
|
Harrow Health Inc |
|
855.3
|
24.0
|
L
 2.7%
H
23.4
24.0
|
L
 -0.4%
H
22.8
25.1
|
L
 -11.1%
H
20.9
30.6
|
L
 -29.1%
H
20.9
37
|
L
 121.1%
H
9.9
59.2
|
L
 239.8%
H
5.4
59.2
|
L
 433.1%
H
3.6
59.2
|
L
 196.5%
H
1.4
59.2
|
HUTCHMED (China) Limited -... |
|
2,352.6
|
13.8
|
L
 0.2%
H
13.7
14.0
|
L
 0.3%
H
13.5
15.1
|
L
 -8.0%
H
11.5
16.6
|
L
 -3.1%
H
11.5
17.1
|
L
 -15.9%
H
11.5
21.9
|
L
 -16.8%
H
7.4
21.9
|
L
 -28.1%
H
7.4
43.9
|
L
H
7.4
43.9
|
ImmunityBio Inc |
|
2,179.7
|
2.5
|
L
 -0.4%
H
2.4
2.5
|
L
 -6.1%
H
2.4
3.0
|
L
 -12.1%
H
2.4
3.5
|
L
 -16.0%
H
2.4
4.3
|
L
 -49.7%
H
2.3
10.5
|
L
 -48.1%
H
1.2
10.5
|
L
H
1.2
40.8
|
L
H
1.2
40.8
|
Ideaya Biosciences Inc |
|
1,495.1
|
17.1
|
L
 5.6%
H
16.1
17.1
|
L
 2.0%
H
15.8
17.3
|
L
 -7.5%
H
13.5
19.1
|
L
 -23.0%
H
13.5
25.6
|
L
 -54.6%
H
13.5
44.4
|
L
 63.3%
H
8.1
47.7
|
L
 279.6%
H
4.4
47.7
|
L
H
3.0
47.7
|
IGM Biosciences Inc |
|
72.9
|
1.2
|
L
 2.5%
H
1.2
1.3
|
L
 1.7%
H
1.1
1.3
|
L
 1.7%
H
0.9
1.3
|
L
 -31.1%
H
0.9
1.9
|
L
 -83.5%
H
0.9
22.5
|
L
 -93.5%
H
0.9
28.2
|
L
 -98.0%
H
0.9
133
|
L
H
0.9
133
|
Inhibikase Therapeutics Inc |
|
141.2
|
1.9
|
L
 -4.0%
H
1.8
2.0
|
L
 -8.2%
H
1.8
2.2
|
L
 -19.8%
H
1.5
2.6
|
L
 -30.2%
H
1.5
3.3
|
L
 -9.5%
H
1.1
4.2
|
L
 -72.3%
H
0.8
8.0
|
L
H
0.8
70.8
|
L
H
0.8
70.8
|
Immix Biopharma Inc |
|
45.5
|
1.6
|
L
 4.5%
H
1.6
1.7
|
L
 5.1%
H
1.6
1.8
|
L
 -15.0%
H
1.3
2.1
|
L
 -19.6%
H
1.3
2.1
|
L
 -25.8%
H
1.3
2.7
|
L
 -4.7%
H
0.7
7.8
|
L
H
0.7
8.7
|
L
H
0.7
8.7
|
Immuneering Corp - Ordinar... |
|
45.6
|
1.3
|
L
 1.6%
H
1.2
1.3
|
L
 -1.6%
H
1.2
1.4
|
L
 -24.4%
H
1.1
1.9
|
L
 -37.1%
H
1.1
2.2
|
L
 -28.3%
H
1
3.8
|
L
 -79.5%
H
1
16.2
|
L
H
1
34.0
|
L
H
1
34.0
|
Immunic Inc |
|
93.9
|
1.0
|
L
 4.3%
H
0.9
1.0
|
L
 8.9%
H
0.9
1.0
|
L
 -13.3%
H
0.8
1.3
|
L
 3.2%
H
0.8
1.4
|
L
 -22.8%
H
0.8
2.1
|
L
 -89.3%
H
0.8
11.8
|
L
 -88.2%
H
0.8
28.2
|
L
 -99.9%
H
0.8
1186.8
|
Incyte Corp. |
|
11,265.1
|
58.2
|
L
 0.8%
H
57.1
58.7
|
L
 2.4%
H
57.1
60.0
|
L
 -3.0%
H
53.6
63.6
|
L
 -19.1%
H
53.6
77.0
|
L
 10.2%
H
50.4
84.0
|
L
 -27.5%
H
50.3
86.3
|
L
 -41.8%
H
50.3
110.4
|
L
 -42.7%
H
50.3
153.2
|
Indaptus Therapeutics Inc |
|
6.9
|
0.5
|
L
H
0.5
0.5
|
L
H
0.5
0.5
|
L
 -40.7%
H
0.4
0.9
|
L
 -42.9%
H
0.4
1.7
|
L
 -81.0%
H
0.4
3.1
|
L
 -85%
H
0.4
4.1
|
L
 -97.6%
H
0.4
63.3
|
L
 -98.5%
H
0.4
8800
|
Indivior Plc |
|
1,124.1
|
9.0
|
L
 -0.6%
H
9
9.3
|
L
 -1.1%
H
9.0
9.5
|
L
 -7.5%
H
8.6
10.2
|
L
 -22.7%
H
7.6
12.4
|
L
 -52.0%
H
7.3
19.1
|
L
 108.6%
H
3
26.5
|
L
 1453.4%
H
0.6
26.5
|
L
 191.6%
H
0.4
26.5
|
InMed Pharmaceuticals Inc |
|
3.3
|
2.7
|
L
 1.9%
H
2.6
2.7
|
L
 -0.7%
H
2.4
2.8
|
L
 -5.6%
H
1.7
2.9
|
L
 -45.1%
H
1.7
8.3
|
L
 -54.8%
H
1.7
15.7
|
L
 -99.4%
H
1.7
710
|
L
 -99.9%
H
1.7
5214
|
L
 -99.9%
H
1.7
32175
|
Inovio Pharmaceuticals Inc |
|
63.8
|
1.7
|
L
 1.2%
H
1.7
1.8
|
L
 8.1%
H
1.6
1.8
|
L
 -17.1%
H
1.4
2.1
|
L
 -16.4%
H
1.4
2.3
|
L
 -82.9%
H
1.4
13.4
|
L
 -41.4%
H
0.3
14.8
|
L
 -78.9%
H
0.3
33.8
|
L
 -82.7%
H
0.3
33.8
|
Insmed Inc |
|
13,209.2
|
72.7
|
L
 3.5%
H
69.9
72.7
|
L
 6.0%
H
68.7
72.7
|
L
 -5.6%
H
60.4
81.5
|
L
 0.2%
H
60.4
84.9
|
L
 192.9%
H
21.9
84.9
|
L
 192.4%
H
16.0
84.9
|
L
 275.8%
H
16.0
84.9
|
L
 221.0%
H
9.0
84.9
|
Innoviva Inc |
|
1,146.8
|
18.3
|
L
 1%
H
18.1
18.4
|
L
 4.3%
H
17.5
18.4
|
L
 5.7%
H
16.7
18.4
|
L
 -1.7%
H
16.7
19.4
|
L
 24.4%
H
14.7
21.3
|
L
 -1.5%
H
10.6
21.3
|
L
 39.5%
H
9.2
21.3
|
L
 6.7%
H
6.4
21.3
|
Inozyme Pharma Inc |
|
59.1
|
0.9
|
L
 -4.2%
H
0.9
1.0
|
L
 3.4%
H
0.9
1.1
|
L
 -5.2%
H
0.7
1.1
|
L
 -32.4%
H
0.7
1.6
|
L
 -79.9%
H
0.7
6.2
|
L
 -78.6%
H
0.7
7.8
|
L
H
0.7
31.7
|
L
H
0.7
31.7
|
Ionis Pharmaceuticals Inc |
|
4,514.6
|
28.4
|
L
 0.2%
H
28.0
28.8
|
L
 1.8%
H
27.6
29.0
|
L
 -13.8%
H
24.0
33.7
|
L
 -9.6%
H
24.0
35.3
|
L
 -30.4%
H
24.0
52.3
|
L
 -30.7%
H
24.0
54.4
|
L
 -48.4%
H
24.0
64.4
|
L
 -56.5%
H
19.6
86.6
|
Ironwood Pharmaceuticals I... |
|
118.1
|
0.7
|
L
 -2.7%
H
0.7
0.8
|
L
 -23.2%
H
0.6
0.8
|
L
 -49.7%
H
0.6
1.6
|
L
 -80.1%
H
0.6
4.0
|
L
 -90.4%
H
0.6
8.5
|
L
 -93.8%
H
0.6
15.7
|
L
 -92.9%
H
0.6
15.7
|
L
 -94.2%
H
0.6
17.7
|
Iterum Therapeutics Plc |
|
37.3
|
1.1
|
L
 2.9%
H
1.1
1.1
|
L
 -2.7%
H
1.1
1.2
|
L
 -21.7%
H
1.1
1.5
|
L
 -29.9%
H
1.1
1.8
|
L
 -24.5%
H
0.8
3.0
|
L
 -74.9%
H
0.6
7.0
|
L
 -97.1%
H
0.6
90.3
|
L
H
0.6
195
|
I-Mab - ADR |
|
68.5
|
0.8
|
L
H
0.8
0.9
|
L
 25.4%
H
0.7
1.0
|
L
 -1.2%
H
0.6
1.0
|
L
 -21.5%
H
0.6
1.1
|
L
 -53.3%
H
0.6
2
|
L
 -93.2%
H
0.6
15.6
|
L
 -93.9%
H
0.6
85.4
|
L
H
0.6
85.4
|
Immuron Limited - ADR |
|
10.8
|
1.9
|
L
 10.5%
H
1.9
1.9
|
L
 11.2%
H
1.6
1.9
|
L
 6.8%
H
1.6
2.1
|
L
 -12.1%
H
1.6
2.3
|
L
 -22.9%
H
1.6
2.9
|
L
 -35.9%
H
1.4
6.0
|
L
 -19.6%
H
1.4
29.0
|
L
H
1.4
29.0
|
Innate Pharma - ADR |
|
165.1
|
2.0
|
L
 1.6%
H
2.0
2.0
|
L
 4.8%
H
1.8
2
|
L
 1.0%
H
1.7
2.2
|
L
 16.6%
H
1.6
2.6
|
L
 -16.2%
H
1.3
3.5
|
L
 -37.7%
H
1.3
4.0
|
L
 -74.6%
H
1.3
12.0
|
L
H
1.3
12.0
|
Jaguar Health Inc |
|
3.6
|
5.5
|
L
 -1.8%
H
5.3
5.6
|
L
 -1.1%
H
5
6.1
|
L
 -10.0%
H
4.0
7.6
|
L
 556.0%
H
0.4
12.5
|
L
 -48.1%
H
0.4
21.6
|
L
 -99.8%
H
0.4
2596.5
|
L
 -99.9%
H
0.4
60345
|
L
H
0.4
999999
|
Jazz Pharmaceuticals plc |
|
6,242.1
|
102.8
|
L
 1.2%
H
100.5
104.5
|
L
 2.3%
H
100.2
104.5
|
L
 -26.3%
H
95.5
142.6
|
L
 -15.2%
H
95.5
148.1
|
L
 -5.9%
H
95.5
148.1
|
L
 -37.4%
H
95.5
169.9
|
L
 -7.6%
H
95.5
189
|
L
 -45.1%
H
86.9
194.7
|
Kineta Inc |
|
3.4
|
0.3
|
L
H
0.3
0.3
|
L
 3.7%
H
0.3
0.3
|
L
 -9.7%
H
0.3
0.4
|
L
 -30%
H
0.3
0.5
|
L
 -42.9%
H
0.3
1.2
|
L
 -96.9%
H
0.3
15.5
|
L
 -99.9%
H
0.3
273
|
L
H
0.3
2888.2
|
Kala Pharmaceuticals Inc |
|
22.3
|
3.5
|
L
 -0.3%
H
3.4
3.5
|
L
 2.7%
H
3.4
3.9
|
L
 -52.0%
H
3.4
7.3
|
L
 -52.3%
H
3.4
11.2
|
L
 -49.2%
H
3.4
11.2
|
L
 -91.2%
H
3.4
56.7
|
L
 -99.3%
H
3.4
734
|
L
H
3.4
1337.5
|
KalVista Pharmaceuticals Inc |
|
596.6
|
12
|
L
 2.2%
H
11.7
12.2
|
L
 4.4%
H
11.4
12.4
|
L
 -3.0%
H
9.2
12.6
|
L
 44.6%
H
8.3
12.9
|
L
 4.4%
H
7.3
15.5
|
L
 -13.3%
H
4.1
17.1
|
L
 8.0%
H
4.1
45
|
L
 -85.9%
H
4.1
129.1
|
Kiniksa Pharmaceuticals Lt... |
|
1,468.1
|
20.2
|
L
 -1.6%
H
20.2
20.6
|
L
 4.7%
H
19.4
21.2
|
L
 -10.6%
H
18.3
24.3
|
L
 9.0%
H
18.1
24.3
|
L
 19.7%
H
16.6
28.2
|
L
 92.1%
H
7.4
28.2
|
L
 10.0%
H
7.4
28.7
|
L
H
5.0
32.9
|
Kiora Pharmaceuticals Inc |
|
8.4
|
2.8
|
L
 1.5%
H
2.7
2.8
|
L
 4.9%
H
2.7
2.9
|
L
 -13.4%
H
2.5
3.4
|
L
 -28.6%
H
2.5
4.1
|
L
 447.1%
H
0.4
5.6
|
L
 -87.5%
H
0.4
26.2
|
L
 -98.8%
H
0.4
327.2
|
L
 -99.9%
H
0.4
21000
|
Karyopharm Therapeutics Inc |
|
42.4
|
5.0
|
L
 12.0%
H
4.4
5.1
|
L
 15.4%
H
4.0
5.1
|
L
 -15.1%
H
3.5
6.7
|
L
 -50%
H
0.6
10.8
|
L
 -74.2%
H
0.6
19.6
|
L
 -95.4%
H
0.6
111.9
|
L
 -98.6%
H
0.6
389.7
|
L
 -99.0%
H
0.6
517.1
|
Kronos Bio Inc |
|
54.3
|
0.9
|
L
 1.1%
H
0.9
0.9
|
L
 14.1%
H
0.8
0.9
|
L
 -4.3%
H
0.7
1.0
|
L
 -10.1%
H
0.7
1.1
|
L
 -13.6%
H
0.7
1.6
|
L
 -84.1%
H
0.7
6
|
L
H
0.7
39.6
|
L
H
0.7
39.6
|
Keros Therapeutics Inc |
|
570.7
|
14.1
|
L
 4.0%
H
13.4
14.2
|
L
 15.5%
H
12.1
14.2
|
L
 24.0%
H
9.1
14.2
|
L
 29.6%
H
9.1
14.2
|
L
 -76.1%
H
9.1
72.4
|
L
 -77.3%
H
9.1
73
|
L
 -47.3%
H
9.1
88.8
|
L
H
9.1
88.8
|
Pasithea Therapeutics Corp |
|
3.7
|
1.4
|
L
 0.7%
H
1.3
1.5
|
L
 -2.8%
H
1.1
1.5
|
L
 26.6%
H
1.0
2.3
|
L
 -44.4%
H
0.9
3.9
|
L
 -80.7%
H
0.9
7.7
|
L
 12.2%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
Kazia Therapeutics Limited... |
|
3.7
|
3.3
|
L
 -6.8%
H
2.9
4.2
|
L
 -14.3%
H
2.9
4.2
|
L
 -31.0%
H
2.9
5.3
|
L
 -53.4%
H
2.9
13.2
|
L
 -80.9%
H
2.9
79
|
L
 -99.1%
H
2.9
397.5
|
L
 -97.8%
H
2.9
792.5
|
L
 -99.8%
H
2.9
1892.6
|
Lexaria Bioscience Corp |
|
24.2
|
1.4
|
L
 -1.4%
H
1.3
1.5
|
L
 2.2%
H
1.3
1.5
|
L
 -0.7%
H
1.3
1.9
|
L
 -27.4%
H
1.2
2.0
|
L
 -38.7%
H
1.2
4.4
|
L
 -65.9%
H
0.7
6.9
|
L
 -85.2%
H
0.7
15.6
|
L
 -59.5%
H
0.7
76.2
|
Lifecore Biomedical Inc |
|
237.0
|
6.4
|
L
 1.0%
H
6.3
6.6
|
L
 10.0%
H
5.9
6.6
|
L
 -2.6%
H
4.8
7.3
|
L
 -1.2%
H
4.8
7.3
|
L
 1.3%
H
3.7
8.0
|
L
 -37.4%
H
1.5
12.0
|
L
 -34.2%
H
1.5
12.9
|
L
 -55.4%
H
1.5
15.6
|
Ligand Pharmaceuticals, In... |
|
2,021.2
|
105.0
|
L
 0.3%
H
101.2
106
|
L
 0.7%
H
100.3
107.6
|
L
 -1.2%
H
93.6
112.6
|
L
 -6.2%
H
93.6
123.5
|
L
 44.8%
H
67.7
129.9
|
L
 61.5%
H
46.8
129.9
|
L
 73.1%
H
46.8
141.8
|
L
 89.5%
H
36.9
179.8
|
Atyr Pharma Inc |
|
275.5
|
3.1
|
L
 2.7%
H
3.0
3.1
|
L
 4.4%
H
2.9
3.2
|
L
 -19.9%
H
2.3
4.0
|
L
 -14.1%
H
2.3
4.7
|
L
 91.4%
H
1.4
4.7
|
L
 -32.0%
H
1.1
4.7
|
L
 4.4%
H
1.1
13.1
|
L
H
1.1
396.1
|
Lipella Pharmaceuticals Inc |
|
6.1
|
2.4
|
L
 -0.4%
H
2.3
2.4
|
L
 -1.6%
H
2.3
2.5
|
L
 6.7%
H
2.0
2.7
|
L
 -15.8%
H
2.0
7.3
|
L
 -58.0%
H
2.0
12
|
L
H
0
61.8
|
L
H
0
61.8
|
L
H
0
61.8
|
Lipocine Inc |
|
16.1
|
3
|
L
 -0.3%
H
3
3.2
|
L
 -2.3%
H
3
3.3
|
L
 -13.0%
H
2.8
3.7
|
L
 -31.4%
H
2.8
5.1
|
L
 -44.9%
H
2.8
11.8
|
L
 -82.4%
H
2.3
18.9
|
L
 -64.6%
H
2.3
41.1
|
L
 -97.8%
H
2.3
326.9
|
Liquidia Corp |
|
1,170.3
|
13.7
|
L
 0.3%
H
13.5
14.1
|
L
 1.9%
H
13.3
14.1
|
L
 -6.9%
H
11.3
15.9
|
L
 6.4%
H
11.3
16.8
|
L
 -0.7%
H
8.3
16.8
|
L
 166.9%
H
3.3
17.0
|
L
 87.9%
H
2.3
17.0
|
L
H
2.3
38.5
|
Lisata Therapeutics Inc |
|
19.5
|
2.3
|
L
 8.7%
H
2.1
2.3
|
L
 15.9%
H
1.9
2.3
|
L
 2.3%
H
1.9
2.6
|
L
 -39.1%
H
1.9
4.1
|
L
 -20.7%
H
1.9
4.2
|
L
 -77.5%
H
1.9
11.7
|
L
 -93.5%
H
1.9
73.4
|
L
 -99.5%
H
1.9
520.5
|
Lantern Pharma Inc |
|
36.9
|
3.4
|
L
 -2.0%
H
3.3
3.7
|
L
 6.5%
H
3.1
3.9
|
L
 -8.8%
H
2.6
4.0
|
L
 -7.3%
H
2.6
6.1
|
L
 -40.7%
H
2.6
7.2
|
L
 -47.8%
H
2.4
12.0
|
L
H
2.4
24.8
|
L
H
2.4
24.8
|
Lexicon Pharmaceuticals Inc |
|
184.4
|
0.5
|
L
 2%
H
0.5
0.5
|
L
H
0.5
0.6
|
L
 41.7%
H
0.3
0.7
|
L
 -26.1%
H
0.3
1.1
|
L
 -68.7%
H
0.3
2.5
|
L
 -77.0%
H
0.3
3.8
|
L
 -72.9%
H
0.3
9.7
|
L
 -92.9%
H
0.3
19.6
|
Lyra Therapeutics Inc |
|
5.9
|
0.1
|
L
H
0.1
0.1
|
L
 -10%
H
0.1
0.1
|
L
 -43.8%
H
0.1
0.2
|
L
 -52.6%
H
0.1
0.2
|
L
 -98.3%
H
0.1
5.7
|
L
 -98.7%
H
0.1
7.0
|
L
H
0.1
22
|
L
H
0.1
22
|
Legend Biotech Corp - ADR |
|
6,023.7
|
32.8
|
L
 -2.0%
H
31.7
33.3
|
L
 2.5%
H
31.7
35.1
|
L
 -13.4%
H
29.3
38.2
|
L
 0.4%
H
29.3
40
|
L
 -30.4%
H
29.3
60.9
|
L
 -15.9%
H
29.3
77.3
|
L
H
23.4
77.3
|
L
H
23.4
77.3
|
Mustang Bio Inc |
|
3.7
|
1.3
|
L
 -0.8%
H
1.3
1.3
|
L
 -4.3%
H
1.3
1.4
|
L
 -7.0%
H
1.2
1.5
|
L
 -76.0%
H
1.2
6.7
|
L
 -92.8%
H
0.1
65
|
L
 -99.8%
H
0.1
705
|
L
 -99.9%
H
0.1
3915
|
L
H
0.1
10012.5
|
Moleculin Biotech Inc |
|
11.7
|
0.9
|
L
 -4.4%
H
0.8
0.9
|
L
 10%
H
0.8
1.1
|
L
 -19.3%
H
0.7
1.3
|
L
 -53.2%
H
0.4
3.7
|
L
 -80.5%
H
0.4
5.5
|
L
 -97.0%
H
0.4
132.8
|
L
 -99.2%
H
0.4
139.5
|
L
H
0.4
862.2
|
Madrigal Pharmaceuticals Inc |
|
6,660.7
|
301.7
|
L
 -2.0%
H
298.4
306.8
|
L
 -4.9%
H
292.5
330.6
|
L
 -10.9%
H
290.0
350.5
|
L
 2.7%
H
282.9
377.5
|
L
 35.7%
H
189
377.5
|
L
 294.2%
H
57.2
377.5
|
L
 268.1%
H
52.3
377.5
|
L
 194.2%
H
5.3
377.5
|
MediWound Ltd |
|
184.8
|
17.1
|
L
 5.0%
H
16.3
17.5
|
L
 4.5%
H
16.0
17.5
|
L
 -11.3%
H
14.1
19.7
|
L
 -3.1%
H
14.1
20.6
|
L
 0.7%
H
12.8
24
|
L
 7.6%
H
7.1
24
|
L
 22.8%
H
7.1
43.5
|
L
 -61.8%
H
7.1
73.3
|
MEI Pharma Inc |
|
13.1
|
2.0
|
L
 1.0%
H
1.9
2
|
L
 5.4%
H
1.5
2.1
|
L
 -17.6%
H
1.5
2.4
|
L
 -31.4%
H
1.5
2.9
|
L
 -39.4%
H
1.5
4.1
|
L
 -81.8%
H
1.5
13.6
|
L
 -95.9%
H
1.5
91.5
|
L
 -95.4%
H
1.5
102.8
|
Macrogenics Inc |
|
79.5
|
1.3
|
L
 6.8%
H
1.1
1.3
|
L
 -2.3%
H
1.1
1.3
|
L
 -38.5%
H
1.0
2.2
|
L
 -58%
H
1.0
3.4
|
L
 -92.2%
H
1.0
16.6
|
L
 -84.2%
H
1.0
21.9
|
L
 -80.5%
H
1.0
36.5
|
L
 -96.2%
H
1.0
39.9
|
Mangoceuticals Inc |
|
13.3
|
2.6
|
L
 22.4%
H
2.1
2.6
|
L
 64.7%
H
1.6
2.6
|
L
 -29.0%
H
1.5
5.2
|
L
 -1.5%
H
1.5
6.2
|
L
 756.7%
H
0.2
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
Mirum Pharmaceuticals Inc |
|
1,933.7
|
39.1
|
L
 0.9%
H
38.4
39.5
|
L
 -1.2%
H
37.8
40.2
|
L
 -11.8%
H
36.9
49
|
L
 -16.7%
H
36.9
54.2
|
L
 65.9%
H
23.1
54.2
|
L
 49.2%
H
17.3
54.2
|
L
 165.3%
H
12.8
54.2
|
L
H
6.5
54.2
|
Milestone Pharmaceuticals Inc |
|
47.5
|
0.9
|
L
 8.5%
H
0.8
0.9
|
L
 15.6%
H
0.8
0.9
|
L
 -62.6%
H
0.6
2.4
|
L
 -55.1%
H
0.6
2.5
|
L
 -45.4%
H
0.6
2.5
|
L
 -87.6%
H
0.6
9.9
|
L
 -63.2%
H
0.6
11.4
|
L
H
0.6
28.0
|
MoonLake Immunotherapeutic... |
|
2,425.0
|
38.3
|
L
 3.7%
H
36.9
38.4
|
L
 9.8%
H
34.8
38.4
|
L
 -3.4%
H
31.4
42.3
|
L
 -12.5%
H
31.4
48.5
|
L
 -9.3%
H
31.4
56.9
|
L
 539.7%
H
4.3
65.0
|
L
H
4.3
65.0
|
L
H
4.3
65.0
|
Mannkind Corp |
|
1,379.5
|
4.5
|
L
 0.2%
H
4.5
4.6
|
L
 -2.6%
H
4.5
4.7
|
L
 -12.9%
H
4.3
5.4
|
L
 -24.5%
H
4.3
6.2
|
L
 11.3%
H
4.0
7.6
|
L
 28.2%
H
2.6
7.6
|
L
 254.7%
H
1.1
7.6
|
L
 -82.0%
H
0.7
36.6
|
Mind Medicine Inc |
|
434.9
|
5.8
|
L
 5.7%
H
5.5
5.8
|
L
 6.3%
H
5.4
5.9
|
L
 -10.5%
H
4.7
7.1
|
L
 -19.4%
H
4.7
10.4
|
L
 -35.2%
H
4.7
10.4
|
L
 -57.9%
H
2.1
20.0
|
L
 -9.7%
H
2.1
86.6
|
L
H
0.0
154.8
|
Medicinova Inc |
|
71.1
|
1.5
|
L
H
1.4
1.5
|
L
 5.1%
H
1.3
1.5
|
L
 -3.3%
H
1.1
1.6
|
L
 -20.8%
H
1.1
2.1
|
L
 3.6%
H
1.1
2.6
|
L
 -53.8%
H
1.1
3.2
|
L
 -73.8%
H
1.1
13.3
|
L
 -67.4%
H
1.1
14.5
|
TNF Pharmaceuticals Inc. |
|
0.5
|
0.2
|
L
 -28%
H
0.2
0.2
|
L
 -35.7%
H
0.2
0.3
|
L
 -53.9%
H
0.2
0.4
|
L
 -84.5%
H
0.2
1.4
|
L
 -92.9%
H
0.2
3.4
|
L
 -95.5%
H
0.1
6.2
|
L
 -97.4%
H
0.1
13.9
|
L
 -100.0%
H
0.1
1973.8
|
NewAmsterdam Pharma Compan... |
|
1,794.4
|
16.3
|
L
 1.9%
H
16
16.6
|
L
 8.1%
H
14.9
17.3
|
L
 -31.0%
H
14.1
24.5
|
L
 -30.6%
H
14.1
24.5
|
L
 -16.0%
H
14.1
27.3
|
L
 65.9%
H
5.6
32.9
|
L
H
5.6
32.9
|
L
H
5.6
32.9
|
Neurocrine Biosciences, Inc. |
|
10,030.4
|
101.4
|
L
 1.3%
H
99.4
102.1
|
L
 11.6%
H
92.3
102.1
|
L
 -7.6%
H
84.2
116.2
|
L
 -29.2%
H
84.2
154.6
|
L
 -23.5%
H
84.2
158.0
|
L
 4.2%
H
75.3
158.0
|
L
 2.4%
H
71.9
158.0
|
L
 138.6%
H
31.3
158.0
|
Minerva Neurosciences Inc |
|
11.2
|
1.6
|
L
 5.3%
H
1.6
1.6
|
L
 10.3%
H
1.5
1.6
|
L
 -1.8%
H
1.2
1.9
|
L
 -28.3%
H
1.2
2.7
|
L
 -36%
H
1.2
3.7
|
L
 -71.5%
H
1.2
15.3
|
L
 -97.1%
H
1.2
121.7
|
L
 -96.5%
H
1.2
126.7
|
Nektar Therapeutics |
|
119.1
|
0.6
|
L
 4.9%
H
0.6
0.7
|
L
 3.2%
H
0.6
0.7
|
L
 -27.3%
H
0.4
0.9
|
L
 -28.1%
H
0.4
1.1
|
L
 -51.5%
H
0.4
1.9
|
L
 -86.5%
H
0.4
5.2
|
L
 -96.7%
H
0.4
26.8
|
L
 -94.6%
H
0.4
111.4
|
NLS Pharmaceutics Ltd |
|
5.9
|
1.5
|
L
 2.1%
H
1.4
1.5
|
L
 8.2%
H
1.4
1.6
|
L
 -5.8%
H
1.3
1.7
|
L
 -23.6%
H
1.3
3.4
|
L
 -72.5%
H
0.1
18.4
|
L
 -96.4%
H
0.1
75.2
|
L
H
0.1
294
|
L
H
0.1
294
|
Nurix Therapeutics Inc |
|
780.7
|
10.2
|
L
 4.5%
H
9.5
10.3
|
L
 12.0%
H
9.2
10.3
|
L
 -25.0%
H
8.2
14.6
|
L
 -46.5%
H
8.2
20.7
|
L
 -29.1%
H
8.2
29.6
|
L
 -19.2%
H
4.2
29.6
|
L
H
4.2
52.4
|
L
H
4.2
52.4
|
NeuroSense Therapeutics Ltd |
|
23.9
|
1.0
|
L
H
1.0
1.1
|
L
 -2.8%
H
1.0
1.1
|
L
 -8.0%
H
0.9
1.2
|
L
 -5.5%
H
0.9
1.3
|
L
 -32.2%
H
0.5
1.5
|
L
 -46.6%
H
0.4
4.5
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
NRX Pharmaceuticals Inc |
|
32.6
|
1.9
|
L
H
1.9
2.0
|
L
 -5.9%
H
1.9
2.1
|
L
 -12.3%
H
1.6
2.3
|
L
 -51.9%
H
1.6
4.0
|
L
 -36.1%
H
1.1
6.0
|
L
 -91.0%
H
1.1
54
|
L
 -98.2%
H
1.1
769.9
|
L
H
1.1
769.9
|
Nuvectis Pharma Inc |
|
207.2
|
8.9
|
L
 1.8%
H
8.8
9.3
|
L
 6.6%
H
8.3
10.2
|
L
 -6.1%
H
7.6
10.7
|
L
 61.4%
H
5.5
10.7
|
L
 31.9%
H
4.4
11.8
|
L
 -7.7%
H
4.4
20.9
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
Nextcure Inc |
|
10.1
|
0.4
|
L
 5.9%
H
0.3
0.4
|
L
 24.1%
H
0.3
0.4
|
L
 -37.9%
H
0.2
0.7
|
L
 -54.4%
H
0.2
0.9
|
L
 -77.1%
H
0.2
1.8
|
L
 -92.5%
H
0.2
5.3
|
L
 -99.0%
H
0.2
39.8
|
L
H
0.2
109
|
Ocugen Inc |
|
198.6
|
0.7
|
L
 4.6%
H
0.7
0.7
|
L
 -1.5%
H
0.6
0.7
|
L
 30.8%
H
0.5
0.8
|
L
 -4.2%
H
0.5
0.8
|
L
 -48.5%
H
0.5
2.1
|
L
 -73.8%
H
0.3
3.1
|
L
 47.8%
H
0.2
18.8
|
L
 -99.9%
H
0.2
552
|
Oculis Holding AG |
|
877.0
|
18.3
|
L
 1.4%
H
18.0
18.6
|
L
 9.1%
H
16.6
18.6
|
L
 -3.7%
H
14
20
|
L
 -19.7%
H
14
23.0
|
L
 55.1%
H
10.8
23.1
|
L
 86.8%
H
6.3
23.1
|
L
H
6.3
23.1
|
L
H
6.3
23.1
|
Ocular Therapeutix Inc |
|
1,162.5
|
7.3
|
L
 2.0%
H
7.1
7.4
|
L
 2.8%
H
6.9
7.8
|
L
 -1.9%
H
5.8
8.0
|
L
 -8.7%
H
5.8
8.9
|
L
 24.7%
H
4.1
11.8
|
L
 82.8%
H
2
11.8
|
L
 41.4%
H
2
24.3
|
L
 -72.3%
H
2
29.2
|
Opus Genetics Inc. |
|
35.9
|
0.8
|
L
 2.7%
H
0.7
0.8
|
L
 7.0%
H
0.7
0.9
|
L
 -31.5%
H
0.7
1.3
|
L
 -32.7%
H
0.7
1.3
|
L
 -54.5%
H
0.7
2.2
|
L
 -71.3%
H
0.7
6.6
|
L
 -90%
H
0.7
14.8
|
L
 -99.8%
H
0.7
390.2
|
Olema Pharmaceuticals Inc |
|
302.0
|
4.4
|
L
 3.8%
H
4.2
4.4
|
L
 17.2%
H
3.8
4.4
|
L
 6.8%
H
2.9
4.8
|
L
 -21.9%
H
2.9
6.7
|
L
 -55.4%
H
2.9
16.6
|
L
 50.9%
H
2
17.8
|
L
H
2
60.3
|
L
H
2
60.3
|
Omeros Corporation |
|
393.7
|
6.8
|
L
 0.3%
H
6.6
6.9
|
L
 0.7%
H
6.6
7.2
|
L
 -24.0%
H
5.6
9.4
|
L
 -27.3%
H
5.6
10.0
|
L
 111.2%
H
3.0
13.6
|
L
 44.6%
H
0.9
13.6
|
L
 -53.1%
H
0.9
25.5
|
L
 -72.0%
H
0.9
30.2
|
Oncternal Therapeutics Inc |
|
1.6
|
0.5
|
L
H
0.5
0.5
|
L
H
0.5
0.5
|
L
H
0.5
0.5
|
L
H
0.5
0.5
|
L
 -93.8%
H
0.5
9.9
|
L
 -49.5%
H
0.3
10.6
|
L
 -80.7%
H
0.3
10.6
|
L
 -99.0%
H
0.3
179.2
|
OptiNose Inc |
|
92.9
|
9.2
|
L
 0.1%
H
9.2
9.2
|
L
 1.1%
H
9.1
9.3
|
L
 58.1%
H
5.4
9.6
|
L
 43.7%
H
5.1
9.6
|
L
 -34.1%
H
0.4
20.0
|
L
 -73.6%
H
0.4
64.5
|
L
 -84.4%
H
0.4
150
|
L
H
0.4
450
|
ORIC Pharmaceuticals Inc |
|
338.8
|
4.8
|
L
 1.7%
H
4.6
4.9
|
L
 -3.1%
H
4.6
5.4
|
L
 -37.5%
H
3.9
7.7
|
L
 -50.2%
H
3.9
14.7
|
L
 -49.8%
H
3.9
14.7
|
L
 22.9%
H
2.4
16.7
|
L
H
2.4
40.8
|
L
H
2.4
40.8
|
Oramed Pharmaceuticals, Inc |
|
87.8
|
2.2
|
L
 -2.3%
H
2.2
2.2
|
L
 1.9%
H
2.1
2.3
|
L
 -10.4%
H
1.8
2.4
|
L
 -5.7%
H
1.8
3.1
|
L
 -2.3%
H
1.8
3.1
|
L
 -67.0%
H
1.7
13.7
|
L
 -32.0%
H
1.7
31.5
|
L
 -73.7%
H
1.7
31.5
|
Outlook Therapeutics Inc |
|
47.3
|
1.5
|
L
 5.8%
H
1.4
1.5
|
L
 5.1%
H
1.3
1.5
|
L
 -2.7%
H
1.1
1.6
|
L
 -35.0%
H
1.1
2.4
|
L
 -82.5%
H
0.9
9.3
|
L
 -99.8%
H
0.9
812
|
L
 -99.5%
H
0.9
1704
|
L
H
0.9
17568
|
Ovid Therapeutics Inc |
|
20.6
|
0.3
|
L
 7.4%
H
0.3
0.3
|
L
 3.6%
H
0.3
0.3
|
L
 -37.0%
H
0.2
0.5
|
L
 -60.8%
H
0.2
0.8
|
L
 -91.0%
H
0.2
3.5
|
L
 -90.9%
H
0.2
4.1
|
L
 -91.5%
H
0.2
9.4
|
L
H
0.2
15.9
|
Phibro Animal Health Corp.... |
|
700.3
|
17.3
|
L
 2.7%
H
16.6
17.3
|
L
 -1.2%
H
16.6
18.4
|
L
 -20.0%
H
16.5
22.5
|
L
 -17.0%
H
16.5
26.6
|
L
 32.6%
H
12.3
26.6
|
L
 -10.2%
H
9.4
26.6
|
L
 -28.3%
H
9.4
31
|
L
 -48.2%
H
9.4
54.6
|
Palisade Bio Inc |
|
3.3
|
0.7
|
L
 2.9%
H
0.7
0.7
|
L
 2.9%
H
0.7
0.7
|
L
 -10%
H
0.6
0.8
|
L
 -51.4%
H
0.6
1.7
|
L
 -85.8%
H
0.6
9.1
|
L
 -99.9%
H
0.4
744.7
|
L
 -100.0%
H
0.4
12015
|
L
 -100.0%
H
0.4
2772900
|
Panbela Therapeutics Inc. |
|
1.4
|
0.3
|
L
 7.7%
H
0.3
0.3
|
L
 -12.5%
H
0.3
0.3
|
L
 -28.2%
H
0.3
0.4
|
L
 -24.3%
H
0.3
0.5
|
L
 -42.9%
H
0.3
0.5
|
L
 -100.0%
H
0.3
46958.4
|
L
 -100.0%
H
0.3
240000
|
L
 -100.0%
H
0.3
384000
|
Puma Biotechnology Inc |
|
141.9
|
2.9
|
L
 -0.7%
H
2.8
2.9
|
L
 1.4%
H
2.8
3.0
|
L
 -14.4%
H
2.6
3.6
|
L
 -3.7%
H
2.6
3.8
|
L
 -42.7%
H
2.2
5.3
|
L
 2.1%
H
1.6
7.7
|
L
 -70.4%
H
1.6
14.1
|
L
 -98.7%
H
1.6
234.7
|
Pacira BioSciences Inc |
|
1,140.7
|
24.7
|
L
 0.7%
H
24.3
25.1
|
L
 0.4%
H
24.1
25.4
|
L
 4.1%
H
21.8
27.6
|
L
 10.2%
H
21.8
27.6
|
L
 -5.6%
H
11.2
31.7
|
L
 -66.2%
H
11.2
76.9
|
L
 -35.3%
H
11.2
82.2
|
L
 -70.9%
H
11.2
85.5
|
Processa Pharmaceuticals Inc |
|
1.2
|
0.2
|
L
 -12%
H
0.2
0.3
|
L
 -12%
H
0.2
0.4
|
L
 -47.6%
H
0.2
0.5
|
L
 -72.8%
H
0.2
0.8
|
L
 -85.9%
H
0.2
3.1
|
L
 -92.3%
H
0.2
5.9
|
L
 -97.8%
H
0.2
14.2
|
L
 -99.6%
H
0.2
83.3
|
PDS Biotechnology Corporation |
|
49.0
|
1.1
|
L
 3.9%
H
1.0
1.1
|
L
 4.9%
H
1
1.2
|
L
 -22.3%
H
0.9
1.4
|
L
 -25.5%
H
0.9
2.2
|
L
 -62.8%
H
0.9
4.4
|
L
 -80.4%
H
0.9
13.7
|
L
 8%
H
0.8
17.9
|
L
H
0.6
517.4
|
Phathom Pharmaceuticals Inc |
|
280.6
|
4.0
|
L
 -4.5%
H
4.0
4.3
|
L
 -17.4%
H
4.0
5.1
|
L
 -27.3%
H
3.8
6.9
|
L
 -42.1%
H
3.8
7.3
|
L
 -57.5%
H
3.8
19.7
|
L
 -72.3%
H
3.8
19.7
|
L
 -86.8%
H
3.8
64.5
|
L
H
3.8
64.5
|
Pharvaris NV |
|
762.9
|
14
|
L
 2.0%
H
13.6
14.3
|
L
 16.7%
H
12.0
14.6
|
L
 -12.3%
H
11.5
16.6
|
L
 -23.8%
H
11.5
19.9
|
L
 -24%
H
11.5
25.5
|
L
 -20.5%
H
1.8
33
|
L
H
1.8
42.9
|
L
H
1.8
42.9
|
Praxis Precision Medicines... |
|
681.3
|
33.8
|
L
 13.3%
H
29.5
34
|
L
 13.6%
H
28.8
34
|
L
 -8.2%
H
26.7
39.6
|
L
 -52.1%
H
26.7
91.8
|
L
 -27.5%
H
26.7
91.8
|
L
 -73.3%
H
11.9
200.0
|
L
H
11.9
914.3
|
L
H
11.9
914.3
|
PainReform Ltd |
|
3.9
|
2.1
|
L
 3.0%
H
2.0
2.1
|
L
 -1.4%
H
1.9
2.2
|
L
 -27.3%
H
1.7
3.5
|
L
 -32.1%
H
1.7
6.7
|
L
 -61.6%
H
0.2
16.6
|
L
 -97.2%
H
0.2
158.5
|
L
H
0.2
471
|
L
H
0.2
471
|
Procaps Group S.A |
|
3,340.6
|
1.5
|
L
H
1.5
1.5
|
L
 -1.4%
H
0.5
1.5
|
L
 93.3%
H
0.5
1.5
|
L
 -15.2%
H
0.5
2.1
|
L
 -46.3%
H
0.5
3.7
|
L
 -81.6%
H
0.5
9.5
|
L
 -85.2%
H
0.5
12.0
|
L
H
0.5
12.0
|
ProQR Therapeutics N.V |
|
119.9
|
1.1
|
L
H
1.1
1.2
|
L
 1.8%
H
1.1
1.3
|
L
 -30.5%
H
1.1
1.7
|
L
 -51.9%
H
1.1
2.7
|
L
 -38.7%
H
1.1
4.6
|
L
 52%
H
0.5
4.6
|
L
 -77.5%
H
0.5
9.5
|
L
 -94.3%
H
0.5
24
|
Plus Therapeutics Inc |
|
11.2
|
0.7
|
L
 -1.5%
H
0.6
0.7
|
L
 -12%
H
0.6
0.8
|
L
 17.9%
H
0.5
2.1
|
L
 -43.6%
H
0.2
2.3
|
L
 -61.0%
H
0.2
2.7
|
L
 -94.9%
H
0.2
18
|
L
 -97.1%
H
0.2
81.3
|
L
 -100.0%
H
0.2
127125
|
PTC Therapeutics Inc |
|
3,737.6
|
47.4
|
L
 2.1%
H
46.0
48.0
|
L
 10.3%
H
42.8
48.6
|
L
 -14.6%
H
37.3
58.0
|
L
 8.1%
H
37.3
58.4
|
L
 91.9%
H
24
58.4
|
L
 10.7%
H
17.5
59.8
|
L
 -4.8%
H
17.5
70.8
|
L
 -33.0%
H
4.0
74.4
|
Protagenic Therapeutics Inc |
|
1.8
|
0.2
|
L
 -7.7%
H
0.2
0.3
|
L
 -20%
H
0.2
0.3
|
L
 -7.7%
H
0.2
0.6
|
L
 -45.5%
H
0.2
0.6
|
L
 -82.5%
H
0.2
1.9
|
L
 -92.8%
H
0.2
3.7
|
L
 -95.2%
H
0.2
28
|
L
 -99.6%
H
0.2
154.6
|
Petros Pharmaceuticals Inc |
|
1.2
|
0.0
|
L
H
0.0
0.0
|
L
 -20%
H
0.0
0.1
|
L
 -42.9%
H
0.0
0.2
|
L
 -86.7%
H
0.0
0.7
|
L
 -94.3%
H
0.0
0.8
|
L
 -99.6%
H
0.0
28.8
|
L
H
0.0
59.6
|
L
H
0.0
59.6
|
Pulmatrix Inc |
|
23.0
|
6.3
|
L
 14.3%
H
5.6
6.5
|
L
 16.9%
H
5.3
6.5
|
L
 -14.7%
H
5.1
8.1
|
L
 3.3%
H
5.1
10.4
|
L
 221.9%
H
1.7
10.4
|
L
 5.3%
H
1.6
10.4
|
L
 -74.8%
H
1.6
60.8
|
L
 -99.6%
H
1.6
2910
|
Polypid Ltd |
|
27.9
|
2.7
|
L
 -0.4%
H
2.7
2.8
|
L
 10.5%
H
2.5
2.8
|
L
 -7.4%
H
2.3
3.0
|
L
 -17.0%
H
2.3
3.5
|
L
 -36.3%
H
2.3
5.1
|
L
 -98.1%
H
2.3
207
|
L
H
2.3
583.5
|
L
H
2.3
583.5
|
Pyxis Oncology Inc |
|
59.1
|
1.0
|
L
 3.2%
H
0.9
1.0
|
L
H
0.9
1.0
|
L
 -9.4%
H
0.8
1.2
|
L
 -36%
H
0.8
1.7
|
L
 -78.8%
H
0.8
5.4
|
L
 -69.2%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
Pharming Group N.V. - ADR |
|
553.3
|
8.1
|
L
H
8.1
8.1
|
L
 0.5%
H
8
8.5
|
L
 -8.1%
H
7.5
9
|
L
 -19.2%
H
7.5
10.0
|
L
 -13.3%
H
6.7
11.1
|
L
 -7.5%
H
6.1
17.8
|
L
H
6.1
22.0
|
L
H
6.1
22.0
|
Purple Biotech Ltd - ADR |
|
7.5
|
2.8
|
L
 13.2%
H
2.5
2.8
|
L
 13.6%
H
2.4
2.8
|
L
 5.2%
H
2.3
3.1
|
L
 -19.8%
H
2.3
3.9
|
L
 -69.2%
H
2.3
20.6
|
L
 -95.5%
H
2.3
71
|
L
 -96.3%
H
2.3
288
|
L
H
2.3
1390
|
Qilian International Holdi... |
|
1,069.4
|
11
|
L
 -3.3%
H
11
11.7
|
L
 9.9%
H
9.4
11.8
|
L
 7.4%
H
8.4
12.9
|
L
 15.2%
H
8.2
12.9
|
L
 185.7%
H
2.7
14.8
|
L
 14.6%
H
1.8
14.8
|
L
H
1
110
|
L
H
1
110
|
Quoin Pharmaceuticals Ltd ... |
|
3.2
|
5.5
|
L
 -8.7%
H
5.5
6.5
|
L
 2.1%
H
5.1
7.2
|
L
 -97.4%
H
5.1
294
|
L
 -98.6%
H
5.1
471.1
|
L
 -98.9%
H
5.1
1099
|
L
 -100.0%
H
5.1
236124
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
RAPT Therapeutics Inc |
|
104.3
|
0.8
|
L
 -1.3%
H
0.8
0.9
|
L
 -8.1%
H
0.8
1.0
|
L
 -27.5%
H
0.8
1.6
|
L
 -34.2%
H
0.8
1.6
|
L
 -90.0%
H
0.8
8.6
|
L
 -96.0%
H
0.8
32.5
|
L
 -95.0%
H
0.8
43.3
|
L
H
0.8
51.2
|
Ultragenyx Pharmaceutical ... |
|
3,351.3
|
35.7
|
L
 2.0%
H
34.7
35.7
|
L
 4.5%
H
33.8
35.7
|
L
 -8.2%
H
29.6
40.2
|
L
 -10.8%
H
29.6
46.5
|
L
 -17.7%
H
29.6
60.4
|
L
 -54.5%
H
29.6
80.4
|
L
 -39.1%
H
29.6
179.7
|
L
 -43.3%
H
29.6
179.7
|
Regeneron Pharmaceuticals,... |
|
61,567.3
|
563.2
|
L
 2.5%
H
545
563.9
|
L
 1.6%
H
544.5
575.2
|
L
 -15.3%
H
526.0
674.8
|
L
 -17.4%
H
526.0
748.3
|
L
 -37.0%
H
526.0
1211.2
|
L
 -22.1%
H
526.0
1211.2
|
L
 -1.0%
H
441
1211.2
|
L
 25.8%
H
271.4
1211.2
|
Regencell Bioscience Holdi... |
|
378.9
|
29.1
|
L
 6.9%
H
27.1
29.5
|
L
 -19.7%
H
27.1
39
|
L
 -7.9%
H
21
69
|
L
 504.2%
H
3.5
69
|
L
 457.9%
H
3.0
69
|
L
 27.4%
H
3.0
69
|
L
H
3.0
69
|
L
H
3.0
69
|
Repligen Corp. |
|
7,303.3
|
130
|
L
 -1.6%
H
125.2
131.5
|
L
 5.8%
H
123.5
135.8
|
L
 -9.9%
H
103.0
147
|
L
 -19.0%
H
103.0
182.5
|
L
 -17.2%
H
103.0
182.5
|
L
 -14.7%
H
103.0
262.3
|
L
 23.1%
H
102.1
327.3
|
L
 305.1%
H
20.1
327.3
|
Regulus Therapeutics Inc |
|
136.5
|
2.1
|
L
 6.2%
H
1.9
2.1
|
L
 15.7%
H
1.8
2.1
|
L
 49.3%
H
1.3
2.1
|
L
 66.1%
H
0.8
2.1
|
L
 -7.2%
H
0.8
2.9
|
L
 -13.4%
H
0.8
3.8
|
L
 -58.3%
H
0.8
23.2
|
L
 -99.9%
H
0.8
2210.4
|
Regenxbio Inc |
|
297.7
|
5.9
|
L
 -3.6%
H
5.9
6.3
|
L
 0.9%
H
5.8
6.8
|
L
 -23.9%
H
5.0
9.1
|
L
 -19.4%
H
5.0
9.1
|
L
 -63.1%
H
5.0
17.5
|
L
 -79.8%
H
5.0
35.7
|
L
 -82.9%
H
5.0
50.3
|
L
H
5.0
85.1
|
Rigel Pharmaceuticals |
|
301.1
|
16.9
|
L
 2.2%
H
16.1
17.1
|
L
 1.0%
H
16.1
17.7
|
L
 -17.1%
H
15.5
21
|
L
 -16.3%
H
15.5
24.5
|
L
 1504.8%
H
0.8
29.8
|
L
 491.2%
H
0.6
29.8
|
L
 915.1%
H
0.6
29.8
|
L
 312.0%
H
0.6
29.8
|
Relmada Therapeutics Inc |
|
9.6
|
0.3
|
L
H
0.3
0.3
|
L
 -3.3%
H
0.3
0.3
|
L
 -3.3%
H
0.2
0.3
|
L
 -21.6%
H
0.2
0.5
|
L
 -93.3%
H
0.2
4.5
|
L
 -98.9%
H
0.2
38.7
|
L
 -99.2%
H
0.2
54
|
L
 -99.5%
H
0.2
54.4
|
RenovoRx Inc |
|
37.3
|
1.0
|
L
 -1.0%
H
1.0
1.0
|
L
 32.5%
H
0.8
1.0
|
L
 6.3%
H
0.8
1.1
|
L
 -32%
H
0.8
1.7
|
L
 -16.4%
H
0.8
1.7
|
L
 -58.0%
H
0.6
5.7
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
Roivant Sciences Ltd |
|
7,242.5
|
10.2
|
L
 1.3%
H
10.0
10.2
|
L
 2.9%
H
9.9
10.3
|
L
 -5.2%
H
8.7
11.4
|
L
 -9.0%
H
8.7
11.5
|
L
 -2.0%
H
8.7
13.1
|
L
 165.0%
H
2.5
13.2
|
L
H
2.5
16.8
|
L
H
2.5
16.8
|
Royalty Pharma plc - Ordin... |
|
14,130.3
|
32.6
|
L
 1.3%
H
32.1
32.7
|
L
 2.0%
H
31.8
32.7
|
L
 -2.4%
H
29.7
34.1
|
L
 6.0%
H
29.7
34.2
|
L
 16.9%
H
24.1
34.2
|
L
 -26.1%
H
24.1
44.7
|
L
H
24.1
56.5
|
L
H
24.1
56.5
|
Repare Therapeutics Inc |
|
51.0
|
1.2
|
L
 4.4%
H
1.2
1.3
|
L
 33.3%
H
0.9
1.3
|
L
 5.3%
H
0.9
1.3
|
L
 -6.3%
H
0.9
1.4
|
L
 -60.3%
H
0.9
4.3
|
L
 -89.1%
H
0.9
18.7
|
L
H
0.9
46.4
|
L
H
0.9
46.4
|
Reviva Pharmaceuticals Hol... |
|
36.5
|
0.8
|
L
 9.9%
H
0.7
0.8
|
L
 14.7%
H
0.7
0.8
|
L
 -27.8%
H
0.5
1.2
|
L
 -55.9%
H
0.5
2.2
|
L
 -74.2%
H
0.5
4.3
|
L
 -62.5%
H
0.5
9.3
|
L
 -92.6%
H
0.5
15.1
|
L
H
0.5
15.1
|
Rezolute Inc |
|
166.5
|
2.8
|
L
 4.2%
H
2.6
2.8
|
L
 11.3%
H
2.4
2.8
|
L
 -18.4%
H
2.2
3.5
|
L
 -43.5%
H
2.2
5.7
|
L
 -16.7%
H
2.2
6.2
|
L
 -24.5%
H
0.7
6.2
|
L
 -37.2%
H
0.7
33.5
|
L
 -96.3%
H
0.7
100
|
Redhill Biopharma - ADR |
|
4.0
|
2.3
|
L
 9.2%
H
1.9
2.5
|
L
 -6.2%
H
1.7
2.5
|
L
 -21.0%
H
1.7
3.3
|
L
 -59.9%
H
1.7
6.8
|
L
 -78.5%
H
1.7
20.3
|
L
 -99.9%
H
1.7
2180
|
L
 -100.0%
H
1.7
11520
|
L
 -100.0%
H
1.7
22220
|
Sage Therapeutics Inc |
|
456.8
|
7.4
|
L
 0.8%
H
7.3
7.5
|
L
 3.8%
H
7.2
7.6
|
L
 -5.5%
H
6.1
8.8
|
L
 4.9%
H
6.1
8.8
|
L
 -43.0%
H
4.6
15.0
|
L
 -78.0%
H
4.6
60.0
|
L
 -76.4%
H
4.6
98.4
|
L
 -87.6%
H
4.6
196.0
|
Sunshine Biopharma Inc |
|
4.5
|
1.3
|
L
 2.5%
H
1.2
1.3
|
L
 -8.1%
H
1.2
1.4
|
L
 -40.5%
H
1.2
3.9
|
L
 -56.9%
H
1.2
3.9
|
L
 -62.4%
H
0.2
3.9
|
L
 -99.6%
H
0.1
480
|
L
 -97.6%
H
0.1
6280
|
L
 -100.0%
H
0.1
320000
|
Scilex Holding Company |
|
31.5
|
6.0
|
L
 -1.6%
H
5.8
6.3
|
L
 2910%
H
0.2
7.6
|
L
 1841.9%
H
0.2
7.6
|
L
 1237.8%
H
0.2
7.6
|
L
 568.9%
H
0.2
7.6
|
L
 -40.9%
H
0.2
16.9
|
L
H
0.2
16.9
|
L
H
0.2
16.9
|
scPharmaceuticals Inc |
|
129.2
|
2.6
|
L
 0.8%
H
2.5
2.6
|
L
 10.8%
H
2.2
2.7
|
L
 -15.7%
H
1.9
3.2
|
L
 -21.7%
H
1.9
3.9
|
L
 -43.0%
H
1.9
5.7
|
L
 -48.9%
H
1.9
12.8
|
L
 -71.4%
H
1.9
12.8
|
L
H
1.9
18.2
|
Scynexis Inc |
|
35.1
|
0.9
|
L
 -1.1%
H
0.9
1.0
|
L
 3.5%
H
0.9
1.0
|
L
 -14.3%
H
0.7
1.1
|
L
 -19.6%
H
0.7
1.2
|
L
 -35.7%
H
0.7
3.1
|
L
 -72.4%
H
0.7
3.9
|
L
 -91%
H
0.7
10.4
|
L
 -99.0%
H
0.7
100.5
|
Shuttle Pharmaceuticals Ho... |
|
1.6
|
0.3
|
L
 -3.9%
H
0.2
0.3
|
L
 -32.4%
H
0.2
0.4
|
L
 -40.5%
H
0.2
0.5
|
L
 -70.2%
H
0.2
1.0
|
L
 -92.2%
H
0.2
4.7
|
L
H
0.2
1010.1
|
L
H
0.2
1010.1
|
L
H
0.2
1010.1
|
SIGA Technologies Inc |
|
427.9
|
6.0
|
L
 1.2%
H
5.9
6.1
|
L
 0.5%
H
5.8
6.3
|
L
 4.0%
H
5.0
6.4
|
L
 -3.7%
H
5.0
6.6
|
L
 -27.2%
H
5.0
12.8
|
L
 -11.5%
H
4.2
27.0
|
L
 5.6%
H
4.2
27.0
|
L
 252.4%
H
0.2
27.0
|
SILO Pharma Inc |
|
4.8
|
1.1
|
L
 4.9%
H
1.0
1.1
|
L
 1.9%
H
1.0
1.1
|
L
 -21.7%
H
1.0
1.4
|
L
 -44.9%
H
1.0
2.1
|
L
 -45.2%
H
0.8
4.5
|
L
 -87.3%
H
0.8
496
|
L
 -91.4%
H
0.8
496
|
L
 -98.3%
H
0.8
496
|
Sol-Gel Technologies Ltd |
|
15.3
|
0.6
|
L
 14.6%
H
0.4
0.7
|
L
 27.9%
H
0.4
0.7
|
L
 -1.8%
H
0.4
0.7
|
L
 -47.6%
H
0.4
1.1
|
L
 -38.9%
H
0.3
1.7
|
L
 -92.4%
H
0.3
7.4
|
L
 -93.3%
H
0.3
16.7
|
L
H
0.3
21
|
Soleno Therapeutics Inc |
|
3,209.1
|
70.0
|
L
 0.1%
H
68.3
70.5
|
L
 4.1%
H
66.1
71
|
L
 39.7%
H
47.2
74
|
L
 49.3%
H
43
74
|
L
 88.4%
H
36.6
74
|
L
 2209.6%
H
0.9
74
|
L
 56.6%
H
0.9
74
|
L
 -86.5%
H
0.9
600
|
Acelyrin Inc |
|
221.6
|
2.2
|
L
H
2.2
2.2
|
L
 -1.4%
H
2.1
2.3
|
L
 -22.0%
H
2.0
2.9
|
L
 10.6%
H
1.8
2.9
|
L
 -54.9%
H
1.8
7.3
|
L
H
1.8
29.9
|
L
H
1.8
29.9
|
L
H
1.8
29.9
|
SELLAS Life Sciences Group... |
|
119.0
|
1.3
|
L
 2.3%
H
1.3
1.3
|
L
 15.9%
H
1.1
1.4
|
L
 21.3%
H
1.0
1.4
|
L
 23.6%
H
0.9
1.8
|
L
 -13.8%
H
0.8
1.8
|
L
 -61.6%
H
0.5
5.6
|
L
 -23.8%
H
0.5
19.4
|
L
 -100.0%
H
0.5
74703
|
Soligenix Inc |
|
6.6
|
2.1
|
L
 1.9%
H
2
2.1
|
L
 -3.7%
H
1.9
2.1
|
L
 -10.6%
H
1.7
2.4
|
L
 -10.6%
H
1.7
2.7
|
L
 -69.8%
H
1.7
85.3
|
L
 -98.7%
H
1.7
240.0
|
L
 -99.4%
H
1.7
717.6
|
L
 -100.0%
H
1.7
7080.1
|
Sonoma Pharmaceuticals Inc. |
|
3.7
|
2.3
|
L
 -2.5%
H
2.2
2.4
|
L
 0.4%
H
2.2
2.8
|
L
 -29.2%
H
1.8
3.7
|
L
 -13.2%
H
1.8
4.5
|
L
 1337.5%
H
0.1
5.9
|
L
 -26.0%
H
0.1
5.9
|
L
 -55.3%
H
0.1
19.6
|
L
 -93.9%
H
0.1
88.7
|
Synaptogenix Inc |
|
2.9
|
2.1
|
L
 -5.4%
H
2.1
2.2
|
L
 -7.0%
H
1.9
2.3
|
L
 -25.9%
H
1.8
2.8
|
L
 -35.8%
H
1.8
3.8
|
L
 -54.5%
H
1.8
5.4
|
L
 -69.1%
H
0.1
8.8
|
L
H
0.1
14.5
|
L
H
0.1
14.5
|
SciSparc Ltd |
|
3.0
|
0.3
|
L
 3.7%
H
0.3
0.3
|
L
H
0.3
0.3
|
L
 -24.3%
H
0.2
0.4
|
L
 -53.3%
H
0.2
0.7
|
L
 -78.3%
H
0.2
1.8
|
L
 -99.7%
H
0.2
102.7
|
L
H
0.2
221
|
L
H
0.2
221
|
ARS Pharmaceuticals Inc |
|
1,460.0
|
14.9
|
L
H
14.4
15.1
|
L
 5.9%
H
13.9
15.1
|
L
 29.1%
H
11.4
15.1
|
L
 18.4%
H
10
15.2
|
L
 76.3%
H
7.6
18.5
|
L
 369.4%
H
2.6
18.5
|
L
H
2.6
63.4
|
L
H
2.6
63.4
|
Sarepta Therapeutics Inc |
|
5,219.4
|
53.8
|
L
 -0.3%
H
53.6
55.5
|
L
 5.4%
H
51.4
56.3
|
L
 -26.9%
H
48.0
81.0
|
L
 -54.4%
H
48.0
120.1
|
L
 -53.9%
H
48.0
173.3
|
L
 -32.8%
H
48.0
173.3
|
L
 -54.6%
H
48.0
181.8
|
L
 306.3%
H
8
181.8
|
Sutro Biopharma Inc |
|
43.6
|
0.5
|
L
 -3.7%
H
0.5
0.6
|
L
 -13.3%
H
0.5
0.6
|
L
 -42.2%
H
0.5
1.0
|
L
 -74.1%
H
0.5
2.2
|
L
 -86.2%
H
0.5
5.2
|
L
 -92.4%
H
0.5
8.7
|
L
 -94.9%
H
0.5
28.3
|
L
H
0.5
28.3
|
Supernus Pharmaceuticals Inc |
|
1,716.9
|
30.8
|
L
 0.2%
H
30.5
31.2
|
L
 -2.9%
H
30.5
32.3
|
L
 -4.7%
H
29.8
34.3
|
L
 -18.5%
H
29.8
40.3
|
L
 6.6%
H
25.5
40.3
|
L
 5.0%
H
22
42.1
|
L
 54.8%
H
17.2
42.1
|
L
 128.4%
H
9.5
61.3
|
Sinovac Biotech, Ltd. |
|
464.9
|
6.5
|
L
H
6.5
6.5
|
L
H
6.5
6.5
|
L
H
6.5
6.5
|
L
H
6.5
6.5
|
L
H
6.5
6.5
|
L
H
6.5
6.5
|
L
H
6.5
6.5
|
L
H
6.5
6.5
|
Savara Inc |
|
519.6
|
3.0
|
L
 2.7%
H
2.9
3.0
|
L
 3.1%
H
2.8
3.1
|
L
 7.5%
H
2.5
3.1
|
L
 2.7%
H
2.3
3.1
|
L
 -37.2%
H
2.3
5.3
|
L
 138.9%
H
1.1
5.7
|
L
 21.9%
H
1
5.7
|
L
 -90.9%
H
0.7
49.6
|
SpringWorks Therapeutics Inc |
|
2,843.4
|
37.9
|
L
 0.5%
H
37.3
39.0
|
L
 4.0%
H
36.1
39.0
|
L
 -22.7%
H
32.8
51.4
|
L
 9.5%
H
32.8
62
|
L
 -10.7%
H
28.2
62
|
L
 -22.9%
H
13.6
62
|
L
 37.1%
H
13.6
96.5
|
L
H
13.6
96.5
|
China SXT Pharmaceuticals Inc |
|
29.7
|
2.2
|
L
 118.2%
H
1.1
2.5
|
L
 -13.3%
H
1.0
2.6
|
L
 -22.9%
H
1.0
3.1
|
L
 426.8%
H
0.3
5.7
|
L
 118.2%
H
0.3
5.7
|
L
 -56.8%
H
0.3
57
|
L
 -94.6%
H
0.3
128
|
L
H
0.3
2335
|
Sanofi - ADR |
|
124,313.7
|
50.9
|
L
 0.7%
H
50.9
51.6
|
L
 -1.2%
H
50.4
52.2
|
L
 -13.9%
H
47.7
59.1
|
L
 0.3%
H
47.7
60.1
|
L
 12.1%
H
45.8
60.1
|
L
 -7.8%
H
36.9
60.1
|
L
 6.6%
H
36.9
60.1
|
L
 -1.5%
H
36.8
60.1
|
Protara Therapeutics Inc |
|
143.4
|
3.9
|
L
 -2.5%
H
3.9
4.1
|
L
 -0.3%
H
3.9
4.4
|
L
 -9.9%
H
3.5
4.8
|
L
 -14.3%
H
3.2
5.3
|
L
 41.8%
H
1.6
10.5
|
L
 -10.6%
H
1.0
10.5
|
L
 -83.4%
H
1.0
67.1
|
L
 -99.4%
H
1.0
800
|
Tarsus Pharmaceuticals Inc |
|
2,049.2
|
49.3
|
L
 -0.3%
H
48.7
50.3
|
L
 6.1%
H
45.9
50.3
|
L
 6.7%
H
40.4
52.6
|
L
 5.9%
H
40.4
57.3
|
L
 49.9%
H
20.1
57.3
|
L
 169.7%
H
10.8
57.3
|
L
H
10.8
63.7
|
L
H
10.8
63.7
|
Theravance Biopharma Inc |
|
431.0
|
8.6
|
L
 0.2%
H
8.5
8.7
|
L
 2.6%
H
8.3
8.8
|
L
 -6.4%
H
7.9
9.6
|
L
 0.5%
H
7.9
10.9
|
L
 -6.3%
H
7.4
10.9
|
L
 -9.3%
H
7.4
12.0
|
L
 -67.7%
H
6.1
31.4
|
L
 -52.2%
H
6.1
43.4
|
TRACON Pharmaceuticals Inc |
|
0.1
|
0.0
|
L
H
0.0
0.0
|
L
H
0.0
0.0
|
L
H
0.0
0.0
|
L
H
0.0
0.0
|
L
 -98.6%
H
0
2.1
|
L
 -100.0%
H
0
1004
|
L
 -100.0%
H
0
4880
|
L
 -100.0%
H
0
73400
|
Tenax Therapeutics Inc |
|
21.1
|
5.3
|
L
 -2.4%
H
5.2
5.5
|
L
 -4.3%
H
5.2
5.7
|
L
 -14.9%
H
5.2
6.8
|
L
 -16.5%
H
5.2
7.9
|
L
 44.6%
H
2.8
7.9
|
L
 -99.5%
H
2.8
1248
|
L
 -99.4%
H
2.8
5888
|
L
 -100.0%
H
2.8
127360
|
TG Therapeutics Inc |
|
6,018.9
|
38.3
|
L
 0.3%
H
37.6
38.9
|
L
 4.4%
H
36.8
39.2
|
L
 -3.9%
H
31
43.3
|
L
 29.7%
H
28.2
43.3
|
L
 173.9%
H
12.9
43.3
|
L
 453.8%
H
3.5
43.3
|
L
 227.0%
H
3.5
56.7
|
L
 132.4%
H
3.3
56.7
|
Third Harmonic Bio Inc |
|
232.7
|
5.2
|
L
 0.6%
H
5.1
5.2
|
L
 41.8%
H
5.0
5.2
|
L
 47.4%
H
3.3
5.2
|
L
 -10.9%
H
3.2
6.4
|
L
 -54.9%
H
3.2
16.9
|
L
H
3.2
24.6
|
L
H
3.2
24.6
|
L
H
3.2
24.6
|
Theratechnologies Inc. |
|
115.9
|
2.5
|
L
 -2.0%
H
2.5
2.7
|
L
 29.9%
H
2.5
3.1
|
L
 59.5%
H
1.2
3.1
|
L
 46.5%
H
1.2
3.1
|
L
 92.4%
H
1.1
3.1
|
L
 -76.2%
H
0.9
11.1
|
L
 -70.1%
H
0.9
17.8
|
L
 -36.4%
H
0.9
45
|
Alpha Teknova Inc |
|
307.8
|
5.8
|
L
 -0.2%
H
5.6
5.9
|
L
 3.0%
H
5.4
6.1
|
L
 2.5%
H
4.3
6.4
|
L
 -28.6%
H
4.3
10.4
|
L
 186.6%
H
1.2
10.4
|
L
 -61.2%
H
1.2
16.2
|
L
H
1.2
30.9
|
L
H
1.2
30.9
|
Tiziana Life Sciences Ltd |
|
125.0
|
1.1
|
L
 20.2%
H
0.9
1.1
|
L
 35.4%
H
0.8
1.1
|
L
 -29.6%
H
0.7
1.5
|
L
 44.6%
H
0.6
1.9
|
L
 67.2%
H
0.5
1.9
|
L
 24.4%
H
0.4
1.9
|
L
 -15.7%
H
0.4
12.2
|
L
H
0.4
12.2
|
Tonix Pharmaceuticals Hold... |
|
108.1
|
15.7
|
L
 -1.0%
H
15.5
16.2
|
L
 -6.9%
H
15.2
17.4
|
L
 -23.5%
H
14.2
37.8
|
L
 -33.3%
H
0.2
58.3
|
L
 -96.9%
H
0.2
672
|
L
 -100.0%
H
0.2
117760
|
L
 -100.0%
H
0.2
1574400
|
L
 -100.0%
H
0.2
6860800000
|
Tenaya Therapeutics Inc |
|
73.2
|
0.5
|
L
 -2.2%
H
0.5
0.5
|
L
 -8.2%
H
0.5
0.5
|
L
 -33.8%
H
0.4
0.7
|
L
 -67.9%
H
0.4
1.4
|
L
 -89.5%
H
0.4
5.0
|
L
 -95.8%
H
0.4
11.3
|
L
H
0.4
32
|
L
H
0.4
32
|
Tempest Therapeutics Inc |
|
25.6
|
7.3
|
L
 0.4%
H
7.1
7.7
|
L
 17.0%
H
6.1
7.7
|
L
 756.5%
H
0.4
7.7
|
L
 682.8%
H
0.4
7.7
|
L
 129.7%
H
0.4
7.7
|
L
 154.5%
H
0.2
9
|
L
 -69.5%
H
0.2
54.6
|
L
 -99.9%
H
0.2
8840.3
|
Trevena Inc |
|
1.0
|
1.1
|
L
 -5.1%
H
1.1
1.1
|
L
 1.8%
H
1.1
1.2
|
L
 -13.9%
H
1.1
1.4
|
L
 -39.8%
H
1.1
1.9
|
L
 -87.8%
H
0.2
11.2
|
L
 -99.5%
H
0.2
305.5
|
L
 -99.7%
H
0.2
2300
|
L
 -100.0%
H
0.2
8481.3
|
2seventy bio Inc |
|
260.6
|
5.0
|
L
 0.2%
H
5.0
5.0
|
L
 0.4%
H
5.0
5.0
|
L
 0.4%
H
4.9
5.0
|
L
 90.8%
H
2.3
5.0
|
L
 7.3%
H
2.3
5.3
|
L
 -68.1%
H
1.5
18.9
|
L
H
1.5
64
|
L
H
1.5
64
|
Titan Pharmaceuticals, Inc... |
|
3.4
|
3.7
|
L
 -0.8%
H
3.7
3.7
|
L
 1.6%
H
3.5
3.8
|
L
H
3.4
4.5
|
L
 -2.9%
H
3.1
4.5
|
L
 -47.5%
H
3.0
14.8
|
L
 354.9%
H
0.3
14.8
|
L
 -48.8%
H
0.3
14.8
|
L
 -99.5%
H
0.3
1800
|
Travere Therapeutics Inc |
|
1,324.5
|
14.9
|
L
 2.4%
H
14.6
15
|
L
 2.9%
H
14.1
15.2
|
L
 -24.8%
H
12.9
21.4
|
L
 -18.8%
H
12.9
25.3
|
L
 157.2%
H
5.1
25.3
|
L
 -49.1%
H
5.1
30.4
|
L
 3.0%
H
5.1
33.1
|
L
 -37.9%
H
5.1
37.0
|
TherapeuticsMD Inc |
|
11.6
|
1.0
|
L
 2.0%
H
1.0
1.0
|
L
 2.0%
H
0.9
1.1
|
L
 36.5%
H
0.7
1.2
|
L
 -4.7%
H
0.7
1.7
|
L
 -46.6%
H
0.7
2.4
|
L
 -92.9%
H
0.7
14.4
|
L
 -97.9%
H
0.7
137.5
|
L
 -99.7%
H
0.7
563
|
Universe Pharmaceuticals INC |
|
1.4
|
3.6
|
L
 -2.7%
H
3.4
3.9
|
L
 1.1%
H
3.1
5.2
|
L
 -7.3%
H
0.1
5.6
|
L
 584.6%
H
0.1
5.6
|
L
 -89.2%
H
0.1
64.8
|
L
 -79.4%
H
0.1
64.8
|
L
H
0.1
179.9
|
L
H
0.1
179.9
|
United Therapeutics Corp |
|
12,787.8
|
284.7
|
L
 -0.2%
H
280.0
287.5
|
L
 1.3%
H
278.4
288.5
|
L
 -9.4%
H
267.0
322.3
|
L
 -20.7%
H
267.0
383.5
|
L
 20.2%
H
233.3
417.8
|
L
 50.8%
H
173.2
417.8
|
L
 172.2%
H
98.4
417.8
|
L
 53.8%
H
74.3
417.8
|
Vericel Corp |
|
2,067.1
|
41.2
|
L
 1%
H
40.6
41.6
|
L
 -0.1%
H
39.8
42.6
|
L
 -11.0%
H
37.8
48.7
|
L
 -30.2%
H
37.8
63
|
L
 -6%
H
37.8
63
|
L
 17.3%
H
17.3
63
|
L
 224.9%
H
12.2
68.9
|
L
 1014.3%
H
1.7
68.9
|
Veru Inc |
|
77.6
|
0.5
|
L
 1.9%
H
0.5
0.5
|
L
 -1.9%
H
0.5
0.6
|
L
 10.4%
H
0.5
0.7
|
L
 -45.9%
H
0.5
1.4
|
L
 -62.7%
H
0.5
1.8
|
L
 -95.5%
H
0.4
24.6
|
L
 -83.4%
H
0.4
24.6
|
L
 -83.2%
H
0.4
24.6
|
Vincerx Pharma Inc |
|
1.5
|
0.3
|
L
H
0.3
0.3
|
L
 7.7%
H
0.2
0.3
|
L
 -61.1%
H
0.2
0.7
|
L
 86.7%
H
0.1
2
|
L
 -68.9%
H
0.1
2
|
L
 -90%
H
0.1
9.4
|
L
H
0.1
26.8
|
L
H
0.1
26.8
|
Dogwood Therapeutics Inc. |
|
8.2
|
4.3
|
L
 14.5%
H
3.6
5.1
|
L
 42.8%
H
2.8
5.8
|
L
 -24.7%
H
2.8
7.2
|
L
 128.3%
H
2.1
29.3
|
L
 848.9%
H
0.1
29.3
|
L
 3.6%
H
0.1
29.3
|
L
H
0.1
29.3
|
L
H
0.1
29.3
|
Viking Therapeutics Inc |
|
2,688.2
|
23.9
|
L
 1.4%
H
21.2
24.1
|
L
 7.7%
H
21.2
27.1
|
L
 -18.7%
H
18.9
30.8
|
L
 -26.7%
H
18.9
36.4
|
L
 -63.0%
H
18.9
81.9
|
L
 831.5%
H
2.0
99.4
|
L
 326.0%
H
2.0
99.4
|
L
H
0.9
99.4
|
Vanda Pharmaceuticals Inc |
|
252.5
|
4.3
|
L
 -0.9%
H
4.3
4.4
|
L
 4.8%
H
4.1
4.5
|
L
 -13.2%
H
3.9
5.0
|
L
 -0.7%
H
3.9
5.2
|
L
 -12.9%
H
3.9
6.8
|
L
 -60.8%
H
3.3
11.9
|
L
 -62.4%
H
3.3
21.9
|
L
 -56.3%
H
3.3
33.4
|
Verrica Pharmaceuticals Inc |
|
45.0
|
0.5
|
L
 2.1%
H
0.4
0.5
|
L
 2.1%
H
0.4
0.6
|
L
 -24.6%
H
0.4
0.7
|
L
 -27.9%
H
0.4
0.8
|
L
 -92.9%
H
0.4
11.4
|
L
 -93.5%
H
0.4
11.4
|
L
 -95.6%
H
0.4
18.4
|
L
H
0.4
23.3
|
Viridian Therapeutics Inc |
|
1,069.9
|
13.1
|
L
 3.8%
H
12.3
13.2
|
L
 9.2%
H
12.1
14.2
|
L
 -13.3%
H
9.9
15.9
|
L
 -27.6%
H
9.9
20.4
|
L
 -13.4%
H
9.9
27.2
|
L
 -22.5%
H
9.5
39
|
L
 62.3%
H
7.1
39
|
L
 -97.2%
H
4.7
661.5
|
Virpax Pharmaceuticals Inc |
|
0.3
|
0.3
|
L
 19.1%
H
0.3
0.3
|
L
 4.2%
H
0.2
0.3
|
L
 -92.3%
H
0.1
3.8
|
L
 -96.7%
H
0.1
11.8
|
L
 -99.8%
H
0.1
98.7
|
L
 -99.9%
H
0.1
587.5
|
L
H
0.1
9000
|
L
H
0.1
9000
|
Vertex Pharmaceuticals, Inc. |
|
125,738.2
|
489.1
|
L
 0.7%
H
485.1
492.2
|
L
 1.0%
H
483.4
502.2
|
L
 -4.5%
H
448.1
515.7
|
L
 15.9%
H
424.1
519.7
|
L
 24.3%
H
378
519.9
|
L
 72.8%
H
233.0
519.9
|
L
 80.8%
H
176.4
519.9
|
L
 291.1%
H
71.5
519.9
|
Viatris Inc |
|
9,024.3
|
7.6
|
L
 2.3%
H
7.4
7.6
|
L
 0.3%
H
7.3
7.7
|
L
 -20.6%
H
6.9
9.7
|
L
 -33.1%
H
6.9
11.5
|
L
 -32.0%
H
6.9
13.6
|
L
 -29.4%
H
6.9
13.6
|
L
 -53.1%
H
6.9
19.2
|
L
 -89.2%
H
6.9
76.7
|
vTv Therapeutics Inc - Ord... |
|
51.5
|
19.7
|
L
 4.7%
H
18.3
19.8
|
L
 5.0%
H
18.3
19.8
|
L
 -6.2%
H
14.6
21.6
|
L
 40.2%
H
13.5
27.0
|
L
 -20.4%
H
12.1
29.2
|
L
 2332.1%
H
0.4
31.0
|
L
 764.0%
H
0.4
31.0
|
L
H
0.4
31.0
|
VYNE Therapeutics Inc |
|
28.1
|
1.9
|
L
 2.8%
H
1.8
1.9
|
L
 18.6%
H
1.6
1.9
|
L
 5.1%
H
1.5
2.0
|
L
 -31.5%
H
1.5
3.0
|
L
 -19.6%
H
1.5
4.3
|
L
 -79.1%
H
1.5
9.9
|
L
 -98.0%
H
1.5
237.6
|
L
H
1.5
2869.9
|
Verona Pharma Plc - ADR |
|
5,009.3
|
58.9
|
L
 1.1%
H
58.1
59.9
|
L
 2.1%
H
57.0
59.9
|
L
 -7.3%
H
47.2
67.4
|
L
 13.6%
H
47.2
70.4
|
L
 266.0%
H
11.4
70.4
|
L
 1354.8%
H
3.4
70.4
|
L
 1276.6%
H
3.4
70.4
|
L
H
2.0
70.4
|
Walgreens Boots Alliance Inc |
|
9,417.0
|
10.9
|
L
 0.8%
H
10.8
10.9
|
L
 1.0%
H
10.8
11.0
|
L
 -2.5%
H
10.0
11.2
|
L
 -13.0%
H
9.3
12.1
|
L
 -38.1%
H
8.1
18.8
|
L
 -75.5%
H
8.1
47.3
|
L
 -75.5%
H
8.1
57.1
|
L
 -87.5%
H
8.1
97.3
|
Windtree Therapeutics Inc |
|
0.9
|
1.1
|
L
 0.9%
H
1.1
1.2
|
L
 -14.3%
H
1.0
1.5
|
L
 -36.7%
H
1.0
3.5
|
L
 -89.6%
H
1.0
16.5
|
L
 -99.6%
H
1.0
737.5
|
L
 -100.0%
H
1.0
64350
|
L
 -100.0%
H
1.0
452700
|
L
 -100.0%
H
1.0
1000036.8
|
Xenetic Biosciences Inc |
|
3.7
|
2.4
|
L
 0.8%
H
2.4
2.5
|
L
 5.7%
H
2.3
2.6
|
L
 -29.8%
H
2.2
3.6
|
L
 -42.7%
H
2.2
4.3
|
L
 -41.3%
H
2.2
5.2
|
L
 -76.4%
H
2.2
11.3
|
L
 -72.4%
H
2.2
58.5
|
L
 -99.7%
H
2.2
4514
|
Xenon Pharmaceuticals Inc |
|
2,687.4
|
35.1
|
L
 3.9%
H
33.2
35.4
|
L
 11.8%
H
31.2
35.4
|
L
 -0.2%
H
26.7
36.5
|
L
 -8.9%
H
26.7
41.4
|
L
 -12.9%
H
26.7
46
|
L
 7.7%
H
24.9
51.0
|
L
 178.4%
H
9.3
51.0
|
L
 121.5%
H
2.1
51.0
|
Xilio Therapeutics Inc |
|
38.8
|
0.8
|
L
 -1.3%
H
0.7
0.8
|
L
 5.6%
H
0.7
0.8
|
L
 -3.9%
H
0.6
0.8
|
L
 -34.2%
H
0.6
1.7
|
L
 -41.4%
H
0.6
1.7
|
L
 -86.8%
H
0.5
5.8
|
L
H
0.5
28.0
|
L
H
0.5
28.0
|
XOMA Corp |
|
253.2
|
21.2
|
L
 3.2%
H
20.6
21.6
|
L
 6.1%
H
20
21.6
|
L
 1.4%
H
18.4
21.9
|
L
 -20.9%
H
18.4
27.5
|
L
 -13.9%
H
18.4
35
|
L
 -10.9%
H
13.5
35
|
L
 -13.2%
H
13.5
46.3
|
L
 -71.4%
H
4.0
98.6
|
XORTX Therapeutics Inc |
|
3.6
|
1.0
|
L
 10.5%
H
0.9
1.0
|
L
 11.8%
H
0.8
1.0
|
L
H
0.8
1.1
|
L
 -5%
H
0.8
1.3
|
L
 -68.9%
H
0.8
3.2
|
L
 -50%
H
0.3
7
|
L
 -10.4%
H
0.3
8.2
|
L
H
0.3
8.2
|
Y-Mabs Therapeutics Inc |
|
212.1
|
4.7
|
L
 3.3%
H
4.5
4.7
|
L
 -2.9%
H
4.5
5.4
|
L
 3.3%
H
3.9
5.4
|
L
 -23.9%
H
3.9
6.9
|
L
 -68.7%
H
3.9
17.8
|
L
 -61.9%
H
2.7
20.9
|
L
 -85.5%
H
2.7
55.2
|
L
H
2.7
55.2
|
Zevra Therapeutics Inc |
|
386.9
|
7.2
|
L
 1.4%
H
6.9
7.3
|
L
 3.6%
H
6.8
7.3
|
L
 -10.3%
H
6.2
8.3
|
L
 -11.2%
H
6.2
8.5
|
L
 58.9%
H
4.2
9.8
|
L
 72.3%
H
3.9
9.8
|
L
 73.1%
H
1.9
22.1
|
L
 -96.0%
H
1.9
418.4
|
ZyVersa Therapeutics Inc |
|
1.8
|
0.7
|
L
 -1.4%
H
0.7
0.7
|
L
 -9.1%
H
0.7
1.2
|
L
 -5.4%
H
0.6
1.9
|
L
 -50.7%
H
0.6
1.9
|
L
 11.1%
H
0.6
6.7
|
L
H
0.1
25
|
L
H
0.1
25
|
L
H
0.1
25
|
Zymeworks BC Inc |
|
802.2
|
11.5
|
L
 2.5%
H
11.1
11.6
|
L
 8.5%
H
10.7
11.6
|
L
 -6.6%
H
9.0
13.3
|
L
 -16.9%
H
9.0
15.3
|
L
 33.0%
H
8.0
17.7
|
L
 115.5%
H
4.1
17.7
|
L
 -68.5%
H
4.1
59.0
|
L
H
4.1
59.0
|
Sagimet Biosciences Inc - ... |
|
71.2
|
2.2
|
L
 9.4%
H
2.0
2.2
|
L
 -4.3%
H
2.0
2.5
|
L
 -42.6%
H
1.7
4.2
|
L
 -49.7%
H
1.7
5.2
|
L
 -44.3%
H
1.7
7.4
|
L
 -71.0%
H
1.7
20.7
|
L
 -71.0%
H
1.7
20.7
|
L
 -71.0%
H
1.7
20.7
|
Ocean Biomedical Inc. |
|
6.6
|
0.0
|
L
H
0.0
0.0
|
L
H
0.0
0.1
|
L
 -33.3%
H
0.0
0.1
|
L
 -92.6%
H
0.0
0.7
|
L
 -97.9%
H
0.0
2.1
|
L
 -98%
H
0.0
7.8
|
L
 -98%
H
0.0
7.8
|
L
 -98%
H
0.0
7.8
|
CervoMed Inc |
|
85.3
|
9.8
|
L
 3.3%
H
9.6
10.4
|
L
 15.3%
H
8.1
10.9
|
L
 4.9%
H
7.1
16.9
|
L
 364.5%
H
1.9
16.9
|
L
 -61.2%
H
1.8
25.7
|
L
 -23.6%
H
1.8
26.4
|
L
 -71.4%
H
1.8
138.8
|
L
 -100.0%
H
1.8
33187.5
|
Dianthus Therapeutics Inc |
|
626.5
|
19.5
|
L
 2.7%
H
18.9
19.7
|
L
 10.7%
H
17.2
19.8
|
L
 -6.0%
H
13.4
22.3
|
L
 -2.5%
H
13.4
25.5
|
L
 -17.5%
H
13.4
32.3
|
L
 2465.8%
H
6.6
33.8
|
L
 2465.8%
H
6.6
33.8
|
L
 2465.8%
H
6.6
33.8
|
Neumora Therapeutics Inc. |
|
105.3
|
0.7
|
L
 3.2%
H
0.6
0.7
|
L
 -4.4%
H
0.6
0.7
|
L
 -44.0%
H
0.6
1.2
|
L
 -68.3%
H
0.6
2.2
|
L
 -93.8%
H
0.6
17.2
|
L
H
0.6
21
|
L
H
0.6
21
|
L
H
0.6
21
|
Agape ATP Corp |
|
93.5
|
1.9
|
L
 17.6%
H
1.6
2
|
L
 41.7%
H
1.3
2
|
L
 81.6%
H
1
2.2
|
L
 40.6%
H
0.9
2.3
|
L
 679.2%
H
0.1
3.5
|
L
 21.4%
H
0.1
3.5
|
L
 21.4%
H
0.1
3.5
|
L
 21.4%
H
0.1
3.5
|
Tourmaline Bio Inc |
|
411.2
|
16.0
|
L
 10.3%
H
14.5
16.1
|
L
 22.2%
H
12.9
16.1
|
L
 -7.6%
H
11.6
18.1
|
L
 -11.1%
H
11.6
18.9
|
L
 2.2%
H
11.6
29.8
|
L
 493.0%
H
2.5
48.3
|
L
 493.0%
H
2.5
48.3
|
L
 493.0%
H
2.5
48.3
|
Barinthus Biotherapeutics ... |
|
29.4
|
0.7
|
L
 4.3%
H
0.7
0.7
|
L
 4.3%
H
0.7
0.7
|
L
 -29.1%
H
0.6
1.1
|
L
 -29.8%
H
0.6
1.2
|
L
 -73.1%
H
0.6
2.7
|
L
 -79.9%
H
0.6
5.1
|
L
 -79.9%
H
0.6
5.1
|
L
 -79.9%
H
0.6
5.1
|
Onconetix Inc |
|
0.9
|
0.1
|
L
H
0.1
0.1
|
L
H
0.1
0.1
|
L
 -50%
H
0.1
0.2
|
L
 -88.7%
H
0.1
1.0
|
L
 -98.9%
H
0.1
21.4
|
L
 -100.0%
H
0.1
320
|
L
 -96.7%
H
0.1
3636
|
L
 -96.7%
H
0.1
3636
|
Talphera Inc. |
|
9.8
|
0.5
|
L
 4.4%
H
0.5
0.5
|
L
 -4%
H
0.5
0.6
|
L
 -18.6%
H
0.5
0.7
|
L
 -28.4%
H
0.5
0.8
|
L
H
0.5
1.2
|
L
H
0.5
1.2
|
L
H
0.5
1.2
|
L
H
0.5
1.2
|
ArriVent BioPharma Inc. |
|
617.1
|
18.1
|
L
 1.3%
H
17.4
18.4
|
L
 -0.1%
H
17.4
18.7
|
L
 -7.0%
H
15.5
20.4
|
L
 -25.7%
H
15.5
29.7
|
L
 17.0%
H
14.4
36.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
Skye Bioscience Inc |
|
44.6
|
1.4
|
L
 -8.9%
H
1.4
1.7
|
L
 2.1%
H
1.3
3.7
|
L
 -37.1%
H
1.1
3.7
|
L
 -45.9%
H
1.1
4.3
|
L
H
1.1
7.2
|
L
H
1.1
7.2
|
L
H
1.1
7.2
|
L
H
1.1
7.2
|
Actuate Therapeutics Inc. |
|
156.3
|
8
|
L
 -2.8%
H
7.9
8.2
|
L
 4.4%
H
7.3
8.2
|
L
 7.2%
H
6.1
8.4
|
L
 -7.2%
H
6.0
11.7
|
L
H
5.5
11.7
|
L
H
5.5
11.7
|
L
H
5.5
11.7
|
L
H
5.5
11.7
|
Bicara Therapeutics Inc. |
|
663.0
|
12.2
|
L
 3.4%
H
10.6
12.2
|
L
 12.9%
H
10.6
12.2
|
L
 -2.3%
H
8.9
14.4
|
L
 0.4%
H
8.9
16.6
|
L
H
8.9
28.1
|
L
H
8.9
28.1
|
L
H
8.9
28.1
|
L
H
8.9
28.1
|
Gelteq Ltd. |
|
8.8
|
0.9
|
L
 6.9%
H
0.9
0.9
|
L
 13.4%
H
0.8
1.0
|
L
 -16.2%
H
0.8
1.3
|
L
 -57.5%
H
0.8
2.9
|
L
H
0.8
5.5
|
L
H
0.8
5.5
|
L
H
0.8
5.5
|
L
H
0.8
5.5
|
Septerna Inc. |
|
262.2
|
5.9
|
L
 -1.5%
H
5.9
6.2
|
L
 3.2%
H
5.5
6.3
|
L
 -5.5%
H
4.7
6.7
|
L
 -65.1%
H
4.2
20.4
|
L
H
4.2
27.6
|
L
H
4.2
27.6
|
L
H
4.2
27.6
|
L
H
4.2
27.6
|
Alpha Cognition Inc |
|
66.0
|
4.1
|
L
 -3.1%
H
4.0
4.8
|
L
 -5.9%
H
4.0
5.1
|
L
 -29.0%
H
3.8
6.2
|
L
 -30.9%
H
3.8
7
|
L
H
3.8
7
|
L
H
3.8
7
|
L
H
3.8
7
|
L
H
3.8
7
|
Atlantic International Corp. |
|
244.7
|
3.9
|
L
 3.2%
H
3.6
4
|
L
H
|
L
H
|
L
H
|
L
H
|
L
H
|
L
H
|
L
H
|
BeiGene Ltd - ADR |
|
24,890.7
|
231.0
|
L
 1.2%
H
227.4
234.2
|
L
 0.3%
H
227.4
250.4
|
L
 -11.6%
H
196.5
284.2
|
L
 10.0%
H
196.5
287.9
|
L
 25.1%
H
172.7
287.9
|
L
 25.1%
H
172.7
287.9
|
L
 25.1%
H
172.7
287.9
|
L
 25.1%
H
172.7
287.9
|
Jupiter Neurosciences Inc |
|
20.5
|
0.6
|
L
 -12.7%
H
0.6
0.7
|
L
H
|
L
H
|
L
H
|
L
H
|
L
H
|
L
H
|
L
H
|
Ascentage Pharma Group Int... |
|
1,629.9
|
18.7
|
L
 -0.8%
H
18.6
19.1
|
L
 0.1%
H
18.6
20.9
|
L
 -4.9%
H
17.6
24.0
|
L
 7.7%
H
17
24.0
|
L
 7.7%
H
17
24.0
|
L
 7.7%
H
17
24.0
|
L
 7.7%
H
17
24.0
|
L
 7.7%
H
17
24.0
|
Metsera Inc. |
|
2,055.8
|
19.6
|
L
 11.5%
H
17.3
19.6
|
L
 39.8%
H
16.0
20.5
|
L
 -35.5%
H
12.3
32.2
|
L
H
12.3
32.8
|
L
H
12.3
32.8
|
L
H
12.3
32.8
|
L
H
12.3
32.8
|
L
H
12.3
32.8
|
Maze Therapeutics Inc. |
|
368.3
|
8.4
|
L
 2.8%
H
8.1
8.7
|
L
 7.4%
H
7.5
9.1
|
L
 -30.3%
H
6.7
12.9
|
L
H
6.7
17
|
L
H
6.7
17
|
L
H
6.7
17
|
L
H
6.7
17
|
L
H
6.7
17
|
Aardvark Therapeutics Inc. |
|
151.9
|
7
|
L
 -7.5%
H
6.9
7.4
|
L
 -2.0%
H
6.9
8.0
|
L
 -25.7%
H
4.9
10.4
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
Cuprina Holdings (Cayman) ... |
|
104.0
|
5.0
|
L
 -0.2%
H
4.7
5.8
|
L
 10.5%
H
4.3
5.8
|
L
H
3.5
5.8
|
L
H
3.5
5.8
|
L
H
3.5
5.8
|
L
H
3.5
5.8
|
L
H
3.5
5.8
|
L
H
3.5
5.8
|